Желудочковые нарушения ритма сердца. Внезапная сердечная смерть. Клинические рекомендации 2025

Российское кардиологическое общество

При участии: Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА), Ассоциации детских кардиологов России, Российского общества холтеровского мониторирования и неинвазивной электрофизиологии (РОХМиНЭ), Общероссийской общественной организации "Российское общество скорой медицинской помощи"

Одобрено Научно-практическим Советом Минздрава Российской Федерации (заседание от 15.08.2025 протокол № 51)

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71-2. doi:10.1136/bmj.312.7023.71.

2. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-e391. doi:10.1161/CIR.0000000000000549.

3. Elliot P, Zamorano JL, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.

4. Андреева Н. С., Реброва О. Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.

5. 5.Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi:10.1093/eurheartj/ehac262.

6. Рыжкова О. П., Кардымон О. Л., Прохорчук Е. Б. и др. Руководство по интерпретации данных последовательности ДНК человека, полученных методами массового параллельного секвенирования (MPS) (редакция 2018, версия 2). Медицинская генетика. 2019;18(2):3-23.

7. Ревишвили А. Ш., Шляхто Е. В., Попов С. В. и др. Российские клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва: ВНОА, 2017. 701 с.

8. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation. 2012;125(8):1043-52. doi:10.1161/CIRCULATIONAHA.111.023846.

9. Stecker EC, Reinier K, Marijon E, et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol. 2014;7(2):212-17.

10. Chen LY, Sotoodehnia N, Bůžková P, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med. 2013;173(1):29-35. doi:10.1001/2013.jamainternmed.744.

11. Marijon E, Uy-Evanado A, Dumas F, et al. Warning Symptoms Are Associated With Survival From Sudden Cardiac Arrest. Ann Intern Med. 2016;164(1):23-9. doi:10.7326/M14-2342.

12. Glinge C, Jabbari R, Risgaard B, et al. Symptoms Before Sudden Arrhythmic Death Syndrome: A Nationwide Study Among the Young in Denmark. J Cardiovasc Electrophysiol. 2015;26(7):761-67. doi:10.1111/jce.12674.

13. Ågesen FN, Lynge TH, Blanche P, et al. Temporal trends and sex differences in sudden cardiac death in the Copenhagen City Heart Study. Heart. 2021;107(16):1303-9. doi:10.1136/heartjnl-2020-318881.

14. Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol. 2011;58(12):1254-61. doi:10.1016/j.jacc.2011.01.049.

15. Van der Werf C, Hendrix A, Birnie E, et al. Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the CAREFUL study): a community-based intervention study. Europace. 2016;18(4):592-601. doi:10.1093/europace/euv059.

16. Макаров Л. М., Комолатова В. Н., Киселева И. И. Распространенность внезапной сердечной смерти у лиц молодого возраста в крупном мегаполисе. Медицинский алфавит. 2014;(3):35-40.

17. Бокерия Л. А., Неминущий Н. М., Постол А. С. Сердечная ресинхронизирующая терапия. Формирование показаний и современных подходов к методу повышения эффективности. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(3):102-16. doi:10.17802/2306-1278-2018-7-3-102-116.

18. Fishman GI, Chugh SS, Dimarco JP, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation. 2010;122(22):2335-48. doi:10.1161/CIRCULATIONAHA.110.976092.

19. Wong CX, Brown A, Lau DH, et al. Epidemiology of Sudden Cardiac Death: Global and Regional Perspectives. Heart Lung Circ. 2019;28(1):6-14. doi:10.1016/j.hlc.2018.08.026.

20. Bougouin W, Lamhaut L, Marijon E, et al. SDEC Co-Investigators. Characteristics and prognosis of sudden cardiac death in Greater Paris: population-based approach from the Paris Sudden Death Expertise Center (Paris-SDEC). Intensive Care Med. 2014;40(6):846-54. doi:10.1007/s00134-014-3252-5.

21. Deo R., Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation. 2012;125(4):620-37. doi:10.1161/CIRCULATIONAHA.111.023838.

22. Gerber Y, Jacobsen SJ, Frye RL, et al. Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation. 2006;113(19):2285-92. doi:10.1161/CIRCULATIONAHA.105.590463.

23. Krahn AD, Connolly SJ, Roberts RS, et al. ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J. 2004;147(5):837-40. doi:10.1016/j.ahj.2003.12.017.

24. Becker LB, Han BH, Meyer PM, et al. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project. N Engl J Med. 1993;329(9):600-6. doi:10.1056/NEJM199308263290902.

25. Zhao D, Post WS, Blasco-Colmenares E, et al. Racial Differences in Sudden Cardiac Death. Circulation. 2019;139(14):1688-97. doi:10.1161/CIRCULATIONAHA.118.036553. Erratum in: Circulation. 2019;139(14):e837. doi:10.1161/CIR.0000000000000672.

26. Fox CS, Evans JC, Larson MG, et al. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation. 2004;110(5):522-7. doi:10.1161/01.CIR.0000136993.34344.41.

27. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104(18):2158-63. doi:10.1161/hc4301.098254.

28. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation. 2011;123(1):46-52. doi:10.1161/CIRCULATIONAHA.110.964999.

29. Heidbuchel H, Willems R, Jordaens L, et al. Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort. Eur J Prev Cardiol. 2019;26(7):764-75. doi:10.1177/2047487319834852.

30. Risgaard B, Winkel BG, Jabbari R, et al. Sports-related sudden cardiac death in a competitive and a noncompetitive athlete population aged 12 to 49 years: data from an unselected nationwide study in Denmark. Heart Rhythm. 2014;11(10):1673-81. doi:10.1016/j.hrthm.2014.05.026.

31. Byrne R, Constant O, Smyth Y, et al. Multiple source surveillance incidence and aetiology of out-of-hospital sudden cardiac death in a rural population in the West of Ireland. European Heart Journal. 2008;29(11):1418-23. doi:10.1093/eurheartj/ehn155.

32. Waldmann V, Karam N, Bougouin W, et al. Burden of coronary artery disease as a cause of sudden cardiac arrest in the young. Journal of the American College of Cardiology. 2019;73(16):2118-20. doi:10.1016/j.jacc.2019.01.064.

33. Waldmann V, Karam N, Rischard J, et al. Low rates of immediate coronary angiography among young adults resuscitated from sudden cardiac arrest. Resuscitation. 2020;147:34-42. doi:10.1016/j.resuscitation.2019.12.005.

34. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.

35. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation. 1999;99(15):1978-83. doi:10.1161/01.cir.99.15.1978.

36. Dekker LRC, Bezzina CR, Henriques JPS, et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation. 2006;114(11):1140-5. doi:10.1161/CIRCULATIONAHA.105.606145.

37. Deo R, Norby FL, Katz R, et al. Development and validation of a sudden cardiac death prediction model for the general population. Circulation. 2016;134(11):806-16. doi:10.1161/CIRCULATIONAHA.116.023042.

38. Yoshinaga M, Ushinohama H, Sato S, et al. Etectrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals. Circulation: Arrhythmia and Electrophysiology. 2013;6(5):932-8. doi:10.1161/CIRCEP.113.000619.

39. Boas R, Sappler N, von Stülpnagel L, et al Periodic repolarization dynamics identifies ICD-responders in non-ischemic cardiomyopathy: a DANISH substudy. Circulation. 2022;145(10):754-64. doi:10.1161/CIRCULATIONAHA.121.056464.

40. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. The New England Journal of Medicine. 2000;342(24):1778-85. doi:10.1056/NEJM200006153422403.

41. Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125(16):1988-96. doi:10.1161/CIRCULATIONAHA.111.048041.

42. Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation. 2019;140(4):293-302. doi:10.1161/CIRCULATIONAHA.118.039410.

43. Cadrin-Tourigny J, Bosman LP, Nozza A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal. 2019;40(23):1850-8. doi:10.1093/eurheartj/ehz103.

44. Steyerberg EW, Vergouwe Y, Steyerberg EW. Towards better clinical prediction models: seven steps for development and an ABCD for validation. European Heart Journal. 2014;35(29):1925-31. doi:10.1093/eurheartj/ehu207.

45. Collins GS, Reitsma JB, Altman DG, et al. TRIPOD Group. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Circulation. 2015;350:g7594. doi:10.1136/bmj.g7594.

46. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ЕОК 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2006;114(10):e385-484. doi:10.1161/CIRCULATIONAHA.106.178233.

47. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867. doi:10.1093/eurheartj/ehv316.

48. Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981;64(6):1167-74. doi:10.1161/01.cir.64.6.1167.

49. Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation. 1985;71(1):63-71. doi:10.1161/01.cir.71.1.63.

50. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.

51. Casella M, Carbucicchio C, Russo E, et al. Electrical storm in systemic sclerosis: Inside the electroanatomic substrate. World J Cardiol. 2014;6(10):1127-30. doi:10.4330/wjc.v6.i10.1127.

52. Apshtein AE, Ideker RE. Ventricular Fibrillation in "Cardiac Electrophysiology. From Cell to Bedside". Saunders Company. 2000:677-684.

53. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm. 2008;5(6):1-62. doi:10.1016/j.hrthm.2008.04.014.

54. Avanzas P, Arroyo-Espliguero R, Cosín-Sales J, et al. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis. 2004;175(1):151-57. doi:10.1016/j.atherosclerosis.2004.03.013.

55. Núñez J, Miñana G, Bodí V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 2011;18(21):3226-33. doi:10.2174/092986711796391633.

56. Suh S, Cho YR, Park MK, et al. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One. 2018;13(2):e0193041. doi:10.1371/journal.pone.0193041.

57. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol. 2000;86(9):897-902. doi:10.1016/s0002-9149(00)01118-8.

58. Pilarczyk K, Carstens H, Heckmann J, et al. The aspartate transaminase/alanine transaminase (DeRitis) ratio predicts mid-term mortality and renal and respiratory dysfunction after left ventricular assist device implantation. Eur J Cardiothorac Surg. 2017;52(4):781-88. doi:10.1093/ejcts/ezx247.

59. Narita K, Ureshino H, Hashimoto S. Sustained ventricular tachycardia caused by subacute thyroiditis. Intern Med J. 2018;48(9):1160-62. doi:10.1111/imj.14018.

60. Tsai IH, Su YJ. Thyrotoxic periodic paralysis with ventricular tachycardia. Electrocardiol 2019;54:93-5. doi:10.1016/j.jelectrocard.2019.04.001.

61. Лебедев Д. С., Васичкина Е. С., Татарский Р. Б. Желудочковые тахиаритмии у детей. Р.Б. — СПб.: 2018. 120 с.

62. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography — summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108(9):1146-62. doi:10.1161/01.CIR.0000073597.57414.A9.

63. Дроздов Д. В., Макаров Л. М., Баркан В. С. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023 Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/1560-4071-2023-5631.

64. Podrid PJ, Graboys TB. Exercise stress testing in the management of cardiac rhythm disorders. Med Clin North Am. 1984;68(5):1139-52. doi:10.1016/s0025-7125(16)31089-6.

65. Prastaro M, D’Amore C, Paolillo S, et al. Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction. Heart Fail Rev. 2015;20(3):305-16. doi:10.1007/s10741-014-9461-8.

66. Zellweger MJ, Hachamovitch R, Kang X, et al. Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J Nucl Cardiol. 2009;16(2):193-200. doi:10.1007/s12350-008-9016-2.

67. Мацкеплишвили С. Т., Саидова М. А., Мироненко М. Ю. и др. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024 Российский кардиологический журнал. 2025;30(2):6271. doi:10.15829/1560-4071-2025-6271. EDN: TNLDFN

68. Volosin K, Stadler RW, Wyszynski R, Kirchhof P. Tachycardia detection performance of implantable loop recorders: results from a large ‘real-life’ patient cohort and patients with induced ventricular arrhythmias. Europace. 2013;15(8):1215-22. doi:10.1093/europace/eut036.

69. de Asmundis C, Conte G, Sieira J, et al. Comparison of the patient-activated event recording system vs. traditional 24 h Holter electrocardiography in individuals with paroxysmal palpitations or dizziness. Europace. 2014; 16(8):1231-5. doi:10.1093/europace/eut411.

70. Kang X, Berman DS, Lewin H, et al. Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J. 1999;137(5):949-57. doi:10.1016/s0002-8703(99)70421-7.

71. Zeliaś A, Stępińska J, Andres J, et al. Ten-year experience of an invasive cardiology centre with out-of-hospital cardiac arrest patients admitted for urgent coronary angiography. Kardiol Pol. 2014;72(8):687-99. doi:10.5603/KP.a2014.0088.

72. Zaman S, Narayan A, Thiagalingam A, et al. Significance of repeat programmed ventricular stimulation at electrophysiology study for arrhythmia prediction after acute myocardial infarction. Pacing Clin Electrophysiol. 2014;37(7):795-802. doi:10.1111/pace.12391.

73. Denes P, Uretz E, Ezri MD, Borbola J. Clinical predictors of electrophysiologic findings in patients with syncope of unknown origin. Arch Intern Med. 1988;148(9):1922-8.

74. Speranzon A, Chicco D, Bonazza P, et al. Brugada Syndrome: Focus for the General Pediatrician. Children (Basel). 2024;11(3):281. doi:10.3390/children11030281.

75. Brignole M, Menozzi C, Moya A, et al. International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation. 2001;104(17):2045-50. doi:10.1161/hc4201.097837.

76. Yuhas J, Mattocks K, Gravelin L, et al. Patients’ attitudes and perceptions of implantable cardioverter-defibrillators: potential barriers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. 2012;35(10):1179-87. doi:10.1111/j.1540-8159.2012.03497.x.

77. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89(1):68-75. doi:10.1161/01.cir.89.1.68.

78. Adler A, van der Werf C, Postema PG, et al. The phenomenon of "QT stunning": the abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9(6):901-8. doi:10.1016/j.hrthm.2012.01.026.

79. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011;8(8):1308-39. doi:10.1016/j.hrthm.2011.05.020.

80. Wilde AAM, Semsarian C, Márquez MF, et al. Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), a branch of the European Society of Cardiology (ESC), the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022;24(8):1307-67. doi:10.1093/europace/euac030.

81. Adler A, Novelli V, Amin AS, et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation. 2020;141(6):418-28. doi:10.1161/CIRCULATIONAHA.119.043132.

82. Casey JP, Støve SI, McGorrian C, et al. NAA10 mutation causing a novel intellectual disability syndrome with Long QT due to N-terminal acetyltransferase impairment. Sci Rep. 2015;5:16022. doi:10.1038/srep16022.

83. Hosseini SM, Kim R, Costain G, et al. Reappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome. Circulation. 2018;138(12):1195-205. doi:10.1161/CIRCULATIONAHA.118.035070.

84. Yamagata K, Horie M, Aiba T, et al. Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome A Japanese Multicenter Registry. Circulation. 2017;135(23):2255-70. doi:10.1161/CIRCULATIONAHA.117.027983.

85. Giudicessi JR, Ackerman MJ. Exercise testing oversights underlie missed and delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia in young sudden cardiac arrest survivors. Heart Rhythm. 2019;16(8):1232-9. doi:10.1016/j.hrthm.2019.02.012.

86. Corrado D, Perazzolo Marra M, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. International Journal Cardiology. 2020;319(15):106-14. doi:10.1016/j.ijcard.2020.06.005.

87. Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genetics in Medicine. 2017;19(2):192-203. doi:10.1038/gim.2016.90.

88. Corrado D, van Tintelen PJ, McKenna WJ, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. European Heart Journal. 2020;41(14):1414-29. doi:10.1093/eurheartj/ehz669.

89. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsynegative sudden unexplained death referred for postmortem genetic testing. Mayo Clinic Proceedings. 2012;87(6):524-39. doi:10.1016/j.mayocp.2012.02.017.

90. Nucifora G, Muser D, Masci PG, et al. Prevalence and prognostic value of concealed structural abnormalities in patients with apparently idiopathic ventricular arrhythmias of left versus right ventricular origin: a magnetic resonance imaging study. Circulation: Arrhythmia and Electrophysiology. 2014;7(3):456-62. doi:10.1161/CIRCEP.113.001172.

91. Curcio A, Mazzanti A, Bloise R, et al. Clinical presentation and outcome of Brugada syndrome diagnosed with the new 2013 criteria. Journal of Cardiovascular Electrophysiology. 2016;27(8):937-43. doi:10.1111/jce.12997.

92. Bjune T, Risgaard B, Kruckow L, et al. Post-mortem toxicology in young sudden cardiac death victims: a nationwide cohort study. Europace. 2018;20(4):614-21. doi:10.1093/europace/euw435.

93. Papadakis M, Raju H, Behr ER, et al. Sudden cardiac death with autopsy findings of uncertain significance: potential for erroneous interpretation. Circulation: Arrhythmia and Electrophysiology. 2013;6(3):588-96. doi:10.1161/CIRCEP.113.000111.

94. Van der Werf C, Hofman N, Tan HL, et al. Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. Heart Rhythm. 2010;7(10):1383-9. doi:10.1016/j.hrthm.2010.05.036.

95. Wong LCH, Roses-Noguer F, Till JA, et al. Cardiac evaluation of pediatric relatives in sudden arrhythmic death syndrome: a 2-center experience. Circulation: Arrhythmia and Electrophysiology. 2014;7(5):800-6. doi:10.1161/CIRCEP.114.001818.

96. Behr ER, Dalageorgou C, Christiansen M, et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. European Heart Journal 2008; 29(13): 1670-1680. doi:10.1093/eurheartj/ehn219.

97. Madhavan M, Friedman PA, Lennon RJ, et al. Implantable cardioverter-defibrillator therapy in patients with ventricular fibrillation out of hospital cardiac arrest secondary to acute coronary syndrome. Journal of the American Heart Association. 2015;4(2):e001255. doi:10.1161/JAHA.114.001255.

98. Gibbs C, Thalamus J, Heldal K, et al. Predictors of mortality in high-risk patients with QT prolongation in a community hospital. Europace. 2018;20(FI1):99-107. doi:10.1093/europace/eux286.

99. Simpson TF, Salazar JW, Vittinghoff E, et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. JAMA Intern Med. 2020;180(5):698-706. doi:10.1001/jamainternmed.2020.0148.

100. Brugada J, Blom N, Sarquella-Brugada G, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337-82. doi:10.1093/europace/eut082.

101. Schupp T, Behnes M, Zworowsky MV, et al. Hypokalemia but not Hyperkalemia is Associated with Recurrences of Ventricular Tachyarrhythmias in ICD Recipients. Clin Lab. 2020;66(3). doi:10.7754/Clin.Lab.2019.190645.

102. Goyal A., Spertus JA., Gosch K., Venkitachalam L., Jones PG., Van den Berghe G., Kosiborod M. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307(2):157-64. doi:10.1001/jama.2011.1967.

103. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77(2):392-7. doi:10.1161/01.cir.77.2.392.

104. Van de Voorde P, Turner NM, Djakow J, et al. European Resuscitation Council Guidelines 2021: Paediatric Life Support. Resuscitation. 2021;161:327-87. doi:10.1016/j.resuscitation.2021.02.015.

105. Soar J, Perkins GD, Maconochie I, et al. European Resuscitation Council Guidelines for Resuscitation: 2018 Update — Antiarrhythmic drugs for cardiac arrest. Resuscitation. 2019;134:99-103. doi:10.1016/j.resuscitation.2018.11.018.

106. Балыкова Л. А., Назарова И. С., Тишина А. Н. Лечение аритмий сердца у детей. Практическая медицина. 2011;53:30-7.

107. Wyse DG, Friedman PL, Brodsky MA, et al.; AVID Investigators. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001;38(6):1718-24. doi:10.1016/s0735-1097(01)01597-2.

108. Ladejobi A, Pasupula DK, Adhikari S, et al. Implantable Defibrillator Therapy in Cardiac Arrest Survivors With a Reversible Cause. Circ Arrhythm Electrophysiol. 2018;11(3):e005940. doi:10.1161/CIRCEP.117.005940.

109. Silvetti MS, Colonna D, Gabbarini F, et al. New Guidelines of Pediatric Cardiac Implantable Electronic Devices: What Is Changing in Clinical Practice? J. Cardiovasc. Dev. Dis. 2024;11(4):99. doi:10.3390/jcdd11040099.

110. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2): S444-64. doi:10.1161/CIR.0000000000000261.

111. Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004;351(7):647-56. doi:10.1056/NEJMoa040325.

112. Sasson C, Rogers MA, Dahl J, Kellermann AL. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3(1):63-81. doi:10.1161/CIRCOUTCOMES.109.889576.

113. Cobb LA., Fahrenbruch CE., Walsh TR., et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA. 1999;281(13):1182-8. doi:10.1001/jama.281.13.1182.

114. Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace. 2019;21(8):1143-4. doi:10.1093/europace/euz132.

115. Van de Voorde P, Turner NM, Djakow J, et al. European Resuscitation Council Guidelines 2021: Paediatric Life Support. Resuscitation. 2021;161:327-87.

116. Ornelas-Dorian C, Rolnick K, Brady W, et al. Assessment and Management of a Child With Wide Complex Tachycardia. Ann Emerg Med. 2024;83(1):42-5. doi:10.1016/j.annemergmed.2023.08.007.

117. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346(12):884-90. doi:10.1056/NEJMoa013029.

118. Kudenchuk PJ, Brown SP, Daya M, et al. Resuscitation Outcomes Consortium Investigators. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2016;374(18):1711-22. doi:10.1056/NEJMoa1514204.

119. Herlitz J, Ekström L, Wennerblom B, et al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation. 1997;33(3):199-205. doi:10.1016/s0300-9572(96)01018-0.

120. Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med. 1998;339(22):1595-601. doi:10.1056/NEJM199811263392204.

121. Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA. 2012;307(11):1161-8. doi:10.1001/jama.2012.294.

122. Maconochie IK, Aickin R, Hazinski MF, et al. Pediatric Life Support Collaborators. Pediatric Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Resuscitation. 2020;156:A120-A155. doi:10.1016/j.resuscitation.2020.09.013.

123. Topjian AA, Raymond TT, Atkins D, et al. Pediatric Basic and Advanced Life Support Collaborators. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16_suppl_2): S469-S523. doi:10.1161/CIR.0000000000000901.

124. Long B, Koyfman A. Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. J Emerg Med. 2017;52(4):484-92. doi:10.1016/j.jemermed.2016.09.010.

125. Tang PT, Do DH, Li A, Boyle NG. Team Management of the Ventricular Tachycardia Patient. Arrhythm Electrophysiol Rev. 2018;7(4):238-46. doi:10.15420/aer.2018.37.2.

126. Ohlow MA, Beierlein A, Müller S, et al. Stable tachycardia with wide QRS complex in pre-hospital emergency medicine. Dtsch Med Wochenschr. 2005;130(47):2694-8. doi:10.1055/s-2005-922056.

127. Patel KK, Spertus JA, Khariton Y, et al. American Heart Association’s Get With the Guidelines–Resuscitation Investigators. Association Between Prompt Defibrillation and Epinephrine Treatment With Long-Term Survival After In-Hospital Cardiac Arrest. Circulation. 2018;137(19):2041-51. doi:10.1161/CIRCULATIONAHA.117.030488.

128. Eckardt L, Breithardt G, Kirchhof P. Approach to wide complex tachycardias in patients without structural heart disease. Heart. 2006;92(5):704-11. doi:10.1136/hrt.2005.063792.

129. Hudson KB, Brady WJ, Chan TC, et al. Electrocardiographic manifestations: ventricular tachycardia. J Emerg Med. 2003;25(3):303-14. doi:10.1016/s0736-4679(03)00207-5.

130. Miller JM, Das MK, Yadav AV, et al. Value of the 12-lead ECG in wide QRS tachycardia. Cardiol Clin. 2006;24(3):439-51. doi:10.1016/j.ccl.2006.03.003.

131. Goldberger ZD, Rho RW, Page RL. Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia. Am J Cardiol. 2008;101(10):1456-66. doi:10.1016/j.amjcard.2008.01.024.

132. Abedin Z. Differential diagnosis of wide QRS tachycardia: A review. J Arrhythm. 2021; 37(5):1162-72. doi:10.1002/joa3.12599.

133. Marill KA, Wolfram S, Desouza IS, et al. Adenosine for wide-complex tachycardia: efficacy and safety. Crit Care Med. 2009;37(9):2512-8. doi:10.1097/CCM.0b013e3181a93661.

134. Sharma AD, Klein GJ, Yee R. Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am J Med. 1990;88(4):337-43.

135. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal. 2020;41(5):655-720. doi:10.1093/eurheartj/ehz467.

136. Ortiz M, Martín A, Arribas F, et al. PROCAMIO Study Investigators. Randomized comparison of intravenous vs. intravenous for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38(17):1329-35. doi:10.1093/eurheartj/ehw230.

137. Griffith MJ, Garratt CJ, Rowland E, et al. Effects of intravenous adenosine on verapamil-sensitive ‘idiopathic’ ventricular tachycardia. American Journal of Cardiology. 1994;73(11):759-64. doi:10.1016/0002-9149(94)90877-x.

138. Buxton AE, Marchlinski FE, Doherty JU, et al. Repetitive, monomorphic ventricular tachycardia: clinical and electrophysiologic characteristics in patients with and patients without organic heart disease. American Journal of Cardiology. 1984;54(8):997-1002. doi:10.1016/s0002-9149(84)80133-2.

139. Buxton AE, Marchlinski FE, Doherty JU, et. al. Hazards of intravenous verapamil for sustained ventricular tachycardia. American Journal of Cardiology. 1987;59(12):1107-10. doi:10.1016/0002-9149(87)90857-5.

140. Rankin AC, Rae AP, Cobbe SM. Misuse of intravenous verapamil in patients with ventricular tachycardia. Lancet. 1987;2(8557):472-4. doi:10.1016/s0140-6736(87)91790-9.

141. Kehr J, Binfield A, Maxwell F, et al. Fascicular tachycardiain infancy and the use of verapamil: a case series and literature review. Arch Dis Child. 2019;104(8):789-92. doi:10.1136/archdischild-2018-315617.

142. Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace. 2014;16(9):1257-83. doi:10.1093/europace/euu194.

143. Kowlgi GN, Cha Y-M. Management of ventricular electrical storm: a contemporary appraisal. Europace. 2020;22(12):1768-80. doi:10.1093/europace/euaa232.

144. Guerra F, Shkoza M, Scappini L, et al. Role of electrical storm as a mortality and morbidity risk factor and its clinical predictors: a meta-analysis. Europacen. 2014;16(3):347-53. doi:10.1093/europace/eut304.

145. Noda T, Kurita T, Nitta T, et al. Significant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac defibrillator. International Journal of Cardiology. 2018;255(15):85-91. doi:10.1016/j.ijcard.2017.11.077.

146. Soar J, Maconochie I, Wyckoff MH, et al. 2019 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations: summary from the basic life support; advanced life support; pediatric life support; neonatal life support; education, implementation, and teams; and first aid task force. Circulation. 2019;140(24):e826-e880. doi:10.1161/CIR.0000000000000734.

147. Eifling M, Razavi M, Massumi A. The evaluation and management of electrical storm. Texas Heart Institute Journal. 2011;38(2):111-21.

148. Chatzidou S, Kontogiannis C, Tsilimigras DI, et al. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator. Journal of the American College of Cardiology. 2018;71(17):1897-906. doi:10.1016/j.jacc.2018.02.056.

149. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-71. doi:10.1001/jama.295.2.165.

150. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996;78(1):43-6. doi:10.1016/s0002-9149(96)00224-x.

151. Martí-Carvajal AJ., Simancas-Racines D., Anand V., Bangdiwala S. Prophylactic lidocaine for myocardial infarction. Cochrane Database Syst Rev 2015; 2015(8): CD008553. doi:10.1002/14651858.CD008553.pub2.

152. Martins RP, Urien JM, Barbarot N, Rieul G, Sellal JM, Borella L, Clementy N, Bisson A, Guenancia C, Sagnard A, Schumacher S, Gandjbakhch E, Duchateau J, Tixier R, Goepp A, Hamon D, Lellouche N, Champ-Rigot L, Milliez P, Marijon E, Varlet E, Garcia R, Degand B, Bouju P, Mabo P, Leclercq C, Behar N, Pavin D, de Chillou C, Sacher F, Galand V. Effectiveness of Deep Sedation for Patients With Intractable Electrical Storm Refractory to Antiarrhythmic Drugs. Circulation 2020; 142(16): 1599-1601. doi:10.1161/CIRCULATIONAHA.120.047468.

153. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation. 2008;117(4):462-9. doi:10.1161/CIRCULATIONAHA.106.686534.

154. Vergara P, Tung R, Vaseghi M, et al. Successful ventricular tachycardia ablation in patients with electrical storm reduces recurrences and improves survival. Heart Rhythm. 2018;15(1):48-55. doi:10.1016/j.hrthm.2017.08.022. Erratum in: Heart Rhythm. 2018;15(3):472. doi:10.1016/j.hrthm.2018.02.002.

155. Haïssaguerre M, Shah DC, Jaïs P, et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet. 2002;359(9307):677-8. doi:10.1016/S0140-6736(02)07807-8.

156. Komatsu Y, Hocini M, Nogami A, et al. Catheter Ablation of Refractory Ventricular Fibrillation Storm After Myocardial Infarction. Circulation. 2019;139(20):2315-25. doi:10.1161/CIRCULATIONAHA.118.037997.

157. Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol. 2009;54(6):522-8. doi:10.1016/j.jacc.2009.03.065.

158. Peichl P, Cihák R., Kozeluhová M, et al. Catheter ablation of arrhythmic storm triggered by monomorphic ectopic beats in patients with coronary artery disease. J Interv Card Electrophysiol. 2010;27(1):51-9. doi:10.1007/s10840-009-9443-2.

159. Fudim M, Boortz-Marx R, Ganesh A, et al. Stellate ganglion blockade for the treatment of refractory ventricular arrhythmias: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2017;28(12):1460-7. doi:10.1111/jce.13324.

160. Do DH, Bradfield J, Ajijola OA, et al. Thoracic Epidural Anesthesia Can Be Effective for the Short-Term Management of Ventricular Tachycardia Storm. J Am Heart Assoc. 2017;6(11):e007080. doi:10.1161/JAHA.117.007080.

161. Vaseghi M, Barwad P, Malavassi Corrales FJ, et al. Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias. J Am Coll Cardiol. 2017;69(25):3070-80. doi:10.1016/j.jacc.2017.04.035.

162. Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart Rhythm. 2014;11(3):360-6. doi:10.1016/j.hrthm.2013.11.028.

163. Le Pennec-Prigent S, Flecher E, Auffret V, et al. Effectiveness of Extracorporeal Life Support for Patients With Cardiogenic Shock Due To Intractable Arrhythmic Storm. Crit Care Med. 2017;45(3):e281-e289. doi:10.1097/CCM.0000000000002089.

164. Mariani S, Napp LC, Lo Coco V, et al. Mechanical circulatory support for life-threatening arrhythmia: A systematic review. Int J Cardiol. 2020;308:42-9. doi:10.1016/j.ijcard.2020.03.045.

165. Muser D, Liang JJ, Castro SA, et al. Outcomes with prophylactic use of percutaneous left ventricular assist devices in high-risk patients undergoing catheter ablation of scarrelated ventricular tachycardia: A propensity-score matched analysis. Heart Rhythm. 2018;15(10):1500-6. doi:10.1016/j.hrthm.2018.04.028.

166. Mathuria N, Wu G, Rojas-Delgado F, et al. Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol. 2017;48(1):27-34. doi:10.1007/s10840-016-0168-8.

167. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.

168. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368.

169. AlJaroudi WA, Refaat MM, Habib RH, et al. Genetic Risk Assessment of Defibrillator Events Investigators. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol. 2015;115(7):924-31. doi:10.1016/j.amjcard.2015.01.020.

170. Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. doi:10.1056/NEJMoa030207.

171. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.

172. Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/NEJMoa2022190.

173. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990-7. doi:10.1093/eurheartj/ehv186.

174. Жарова О. П., Басаргина Е. Н., Фисенко А. П. и др. Эффективность медикаментозной терапии хронической сердечной недостаточности у детей раннего возраста с дилатационной кардиомиопатией. Российский педиатрический журнал. 2019;22(4):219-25. doi:10.18821/1560-9561-2019-22-4-219-225.

175. Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. J Heart Lung Transplant. 2014;33(9):888-909. doi:10.1016/j.healun.2014.06.002.

176. Das BB. A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children. Children (Basel) 2024;11(7):859. doi:10.3390/children11070859.

177. Rupp S, Apitz C, Tholen L, et al. Upgraded heart failure therapy leads to an improved out-come of dilated cardiomyopathy in infants and toddlers. Cardiol Young. 2015;25(7):1300-5. doi:10.1017/S1047951114002406.

178. Chavey WE, Hogikyan RV, Van Harrison R, Nicklas JM. Heart Failure Due to Reduced Ejection Fraction: Medical Management. Am Fam Physician. 2017;95(1):13-20.

179. Castro Díez C, Khalil F, Schwender H, et al. Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey. BMJ Paediatr Open. 2019;3(1):e000365. doi:10.1136/bmjpo-2018-000365.

180. Bogle C, Colan SD, Miyamoto SD, et al. American Heart Association Young Hearts Pediatric Heart Failure and Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts). Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. Circulation. 2023;148(2):174-95. doi:10.1161/CIR.0000000000001151.

181. Nguyen KT, Vittinghoff E, Dewland TA, et al. Ectopy on a Single 12-Lead ECG, Incident Cardiac Myopathy, and Death in the Community. J Am Heart Assoc. 2017;6(8):e006028. doi:10.1161/JAHA.117.006028.

182. Dukes JW, Dewland TA, Vittinghoff E, et al. Ventricular Ectopy as a Predictor of Heart Failure and Death. J Am Coll Cardiol. 2015;66(2):101-9. doi:10.1016/j.jacc.2015.04.062.

183. Gill JS, Mehta D, Ward DE, Camm AJ. Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br Heart J. 1992;68(4):392-7. doi:10.1136/hrt.68.10.392.

184. Shimizu W. Arrhythmias originating from the right ventricular outflow tract: how to distinguish "malignant" from "benign"? Heart Rhythm. 2009;6(10):1507-11. doi:10.1016/j.hrthm.2009.06.017.

185. Jamil HA, Mohammed SA, Gierula J, et al. Prognostic Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. Am J Cardiol. 2019;123(3):409-13. doi:10.1016/j.amjcard.2018.10.040.

186. Dabbagh GS, Bogun F. Predictors and Therapy of Cardiomyopathy Caused by Frequent Ventricular Ectopy. Curr Cardiol Rep. 2017;19(9):80. doi:10.1007/s11886-017-0887-1.

187. Hyman MC, Mustin D, Supple G, et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm. 2018;15(2):159-63. doi:10.1016/j.hrthm.2017.12.018.

188. Макарова А., Евдокименко А., Ибрагимова Т. М., Оморова Э. Влияние этацизина и атенолола на аритмии у больных с различными заболеваниями сердца. Здравоохранение Кыргызстана. 2009;(1):72-4.

189. Царегородцев Д. А., Седов А. В., Мельник Н. В. и др. Новые возможности применения неинвазивных электрофизиологических предикторов внезапной сердечной смерти: прогнозирование эффективности и безопасности антиаритмической терапии. Кардиология и сердечно-сосудистая хирургия. 2015;8(6):114-21.

190. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. The New England Journal of Medicine. 1977;297(14):750-7. doi:10.1056/NEJM197710062971404.

191. 191 Engström G, Hedblad B, Janzon L, Juul-Möller S. Ventricular arrhythmias during 24-h ambulatory ECG recording: incidence, risk factors and prognosis in men with and without a history of cardiovascular disease. J Intern Med. 1999;246(4):363-72. doi:10.1046/j.1365-2796.1999.00509.x.

192. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circulation: Arrhythmia and Electrophysiology. 2014;7(2):237-43. doi:10.1161/CIRCEP.113.000805.

193. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clinical Electrophysiology. 2015;1(3):116-23. doi:10.1016/j.jacep.2015.04.005.

194. Primeau R, Agha A, Giorgi C, Shenasa M. Long term efficacy and toxicity of amiodarone in the treatment of refractory cardiac arrhythmias. Canadian Journal of Cardiology. 1989;5(2):98-104.

195. Bertels RA, Kammeraad JAE, Zeelenberg AM, et al. The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study. Pediatr Cardiol. 2021;42(4):883-90. doi:10.1007/s00246-021-02556-7.

196. Mont L, Seixas T, Brugada P, et al. Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. The American Journal of Cardiology. 1991;68(9):897-900. doi:10.1016/0002-9149(91)90405-a.

197. Toivonen L, Nieminen M. Persistent ventricular tachycardia resulting in left ventricular dilatation treated with verapamil. International Journal of Cardiology. 1986;13(3):361-5. doi:10.1016/0167-5273(86)90120-8.

198. Singh B, Kaul U, Talwar KK, Wasir HS. Reversibility of tachycardia induced cardiomyopathy following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clinical Electrophysiology. 1996;19(9):1391-2. doi:10.1111/j.1540-8159.1996.tb04222.x.

199. Stec S, Sikorska A, Zaborska B, et al. Benign symptomatic premature ventricular complexes: short– and long– term efficacy of antiarrhythmic drugs and radiofrequency ablation. Polish Heart Journal (Kardiologia Polska). 2012;70(4):351-8.

200. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144(6):e10. doi:10.1067/mhj.2002.125516.

201. Kuhlkamp V, Mewis C, Mermi J, et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d, l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol. 1999;33(1):46-52. doi:10.1016/s0735-1097(98)00521-x.

202. Capucci A, Di Pasquale G, Boriani G. A double-blind crossover comparison of flecainide and slow-release mexiletine in the treatment of stable premature ventricular complexes. Int J Clin Pharmacol Res. 1991;11(1):23-33.

203. Лоскутов Н. С., Нагорный М. Б. Этацизин в коррекции доброкачественных желудочковых нарушений ритма у больных ИБС и гипертонической болезнью. Известия Российской военно-медицинской академии. 2022;41(S2):272-6.

204. Соколов С. Ф., Бакалов С. А., Миронова Н. А. и др. Эффективность и безопасность аллапинина при краткосрочном и длительном лечении больных с доброкачественной желудочковой экстрасистолией. Кардиология. 2014;(1):20-6.

205. Oeffl N, Schober L, Faudon P, et al. Antiarrhythmic Drug Dosing in Children-Review of the Literature. Children (Basel). 2023;10(5):847. doi:10.3390/children10050847.

206. Hoffmann A, Bühler FR, Burckhardt D. High-grade ventricular ectopic activity and 5-year survival in patients with chronic heart disease and in healthy subjects. Cardiolog 1983;70 Suppl 1:82-7. doi:10.1159/000173635.

207. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol. 1993;22(4):1111-6. doi:10.1016/0735-1097(93)90424-y.

208. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704. doi:10.1016/j.jacc.2004.11.043.

209. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730-7. doi:10.1136/bmj.318.7200.1730.

210. Ladouceur M, Waldmann V, Bartoletti S, et al. Ventricular arrhythmia in congenital heart diseases with a systemic right ventricle, International Journal of Cardiology Congenital Heart Disease. 2023;(13):100463. doi:10.1016/j.ijcchd.2023.100463.

211. Ono K, Iwasaki YK, Akao M, et al.; Japanese Circulation Society and; Japanese Heart Rhythm Society Joint Working Group. JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. J Arrhythm. 2022;38(6):833-973. doi:10.1002/joa3.12714.

212. Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52. doi:10.1186/1471-2261-13-52.

213. Cleophas TJ, Zwinderman AH. Beta-blockers and heart failure: meta-analysis of mortality trials. Int J Clin Pharmacol Ther. 2001;39(9):383-8. doi:10.5414/cpp39383.

214. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol. 1997;80(9B):35J-39J. doi:10.1016/s0002-9149(97)00837-0.

215. Al-Gobari M, Al-Aqeel S, Gueyffier F, Burnand B. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. BMJ Open. 2018;8(7):e021108. doi:10.1136/bmjopen-2017-021108.

216. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7(7):865-9. doi:10.1016/j.hrthm.2010.03.036.

217. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet. 1997;349(9053):667-74. doi:10.1016/s0140-6736(96)09145-3.

218. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet. 1997;349(9053):675-82. doi:10.1016/s0140-6736(96)08171-8.

219. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-8. doi:10.1056/NEJM199103213241201.

220. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327(4):227-33. doi:10.1056/NEJM199207233270403.

221. Ho AT, Pai SM, Timothy P, Pai RG. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2005;28(7):647-53. doi:10.1111/j.1540-8159.2005.00164.x.

222. Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8(9):1469-75. doi:10.1016/j.hrthm.2011.04.015.

223. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. doi:10.1056/NEJMoa043399.

224. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791-8. doi:10.1016/s0735-1097(97)00220-9.

225. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748-54. doi:10.1161/01.cir.102.7.748.

226. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. Am J Cardiol. 1988;62(2):41A-45A. doi:10.1016/s0002-9149(88)80084-5.

227. Mahé I, Chassany O, Grenard AS, et al. Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction. Am J Cardiovasc Drugs. 2003;3(1):33-41. doi:10.2165/00129784-200303010-00004.

228. Masarone D, Limongelli G, Rubino M, et al. Management of Arrhythmias in Heart Failure. J Cardiovasc Dev Dis. 2017;4(1):3. doi:10.3390/jcdd4010003.

229. Podrid P, Lown B. Selection of an antiarrhythmic drug to protect against ventricular fibrillation. In Proceedings of the first US-USSR Symposium on Sudden Death. DHEW publ. no. (NIH) 1978:259-78.

230. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993;329(7):452-8. doi:10.1056/NEJM199308123290702.

231. Aiba T, Kurita T, Taguchi A, et al. Long-term efficacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrhythmia and structural heart disease. Circ J. 2002;66(4):367-71. doi:10.1253/circj.66.367.

232. Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2004;110(2):112-6. doi:10.1161/01.CIR.0000134957.51747.6E.

233. Sobiech M, Lewandowski M, Zając D, et al. Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks. Kardiol Pol. 2017;75(10):1027-32. doi:10.5603/KP.2017.0189.

234. AbdelWahab A, Sapp J. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate. Curr Cardiol Rep. 2017;19(11):105. doi:10.1007/s11886-017-0924-0.

235. Sapp JL, Wells GA, Parkash R, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016;375(2):111-21. doi:10.1056/NEJMoa1513614.

236. Deyell MW, Steinberg C, Doucette S, et al. Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. J Cardiovasc Electrophysiol. 2018;29(4):603-8. doi:10.1111/jce.13431.

237. Gao D, Van Herendael H, Alshengeiti L, et al. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. J Cardiovasc Pharmacol. 2013;62(2):199-204. doi:10.1097/FJC.0b013e31829651fe.

238. Kavey RE, Blackman MS, Sondheimer HM. Phenytoin therapy for ventricular arrhythmias occurring late after surgery for congenital heart disease. Am Heart J. 1982;104(4 Pt 1):794-8. doi:10.1016/0002-8703(82)90013-8.

239. Conolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101(11):1297-302. doi:10.1161/01.cir.101.11.1297.

240. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. Journal of Cardiovascular Electrophysiology. 2010;21(1):47-53. doi:10.1111/j.1540-8167.2009.01563.x.

241. Hohnloser SH, Kuck KH, Dorian P, et al. On behalf of the DINAMIT investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. The New England Journal of Medicine. 2004;351(24):2481-8. doi:10.1056/NEJMoa041489.

242. Steinbeck G, Andresen D, Seidl K. Defibrillator Implantation Early after Myocardial Infarction. Immediate Risk-Stratification Improves Survival (IRIS). The New England Journal of Medicine. 2009;361:1427-36. doi:10.1056/NEJMoa0901889.

243. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. The New England Journal of Medicine. 1996;335(26):1933-40. doi:10.1056/NEJM199612263352601.

244. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. The New England Journal of Medicine. 1999;341(25):1882-90. doi:10.1056/NEJM199912163412503.

245. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine. 2002;346(12):877-83. doi:10.1056/NEJMoa013474.

246. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. The New England Journal of Medicine. 2004;350(21):2140-50. doi:10.1056/NEJMoa032423.

247. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at risk for ventricular arrhythmias after coronary artery bypass graft surgery (Coronary Artery Bypass Graft (CABG) Patch Trial Investigators). The New England Journal of Medicine. 1997;337(22):1569-75. doi:10.1056/NEJM199711273372201.

248. Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH). The New England Journal of Medicine. 2016;375(13):1221-30. doi:10.1056/NEJMoa1608029.

249. Bänsch D, Antz M, Boczor S, et al. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy The Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453-8. doi:10.1161/01.cir.0000012350.99718.ad.

250. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone Versus Implantable Cardioverter-Defibrillator: Randomized Trial in Patients With Nonischemic Dilated Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia-AMIOVIR T. Journal of the American College of Cardiology. 2003;41(10):1707-12. doi:10.1016/s0735-1097(03)00297-3.

251. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-8. doi:10.1056/NEJMoa033088.

252. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004292(23):2874-9. doi:10.1001/jama.292.23.2874.

253. Algalarrondo V, Perault R, Bories MC, et al. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation. Arch Cardiovasc Dis. 2018;111(12):758-65. doi:10.1016/j.acvd.2018.05.004.

254. Sandner SE, Wieselthaler G, Zuckermann A, et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation. 2001;104(12 Suppl 1): I171-6. doi:10.1161/hc37t1.094916.

255. Cleland JG, Daubert JC, Erdmann E, et al.; CARE-HF study Steering Committee and Investigators. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail. 2001;3(4):481-9. doi:10.1016/s1388-9842(01)00176-3.

256. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-95. doi:10.1056/NEJMoa1009540.

257. Eickholt C, Siekiera M, Kirmanoglou K, et al. Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia. PLoS One. 2012;7(11):e48926. doi:10.1371/journal.pone.0048926.

258. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289(20):2685-94. doi:10.1001/jama.289.20.2685.

259. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003;289(6):730-40. doi:10.1001/jama.289.6.730.

260. McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004;141(5):381-90. doi:10.7326/0003-4819-141-5-200409070-00101.

261. Cleland JG, Coletta AP, Lammiman M, et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail. 2005;7(6):1070-5. doi:10.1016/j.ejheart.2005.09.006.

262. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27(16):1928-32. doi:10.1093/eurheartj/ehl099.

263. Daubert C, Gold MR, Abraham WT, et al.; REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54(20):1837-46. doi:10.1016/j.jacc.2009.08.011.

264. Linde C, Gold MR, Abraham WT, et al.; REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction Study Group. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34(33):2592-9. doi:10.1093/eurheartj/eht160.

265. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34(46):3547-56. doi:10.1093/eurheartj/eht290.

266. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015;101(22):1800-6. doi:10.1136/heartjnl-2015-307634.

267. Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36(30):1983-9. doi:10.1093/eurheartj/ehv242.

268. Jacobsson J, Reitan C, Carlson J, et al. Atrial fibrillation incidence and impact of biventricular pacing on long-term outcome in patients with heart failure treated with cardiac resynchronization therapy. BMC Cardiovasc Disord. 2019;19(1):195. doi:10.1186/s12872-019-1169-1.

269. Healey JS, Hohnloser SH, Exner DV, et al. RAFT Investigators. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012;5(5):566-70. doi:10.1161/CIRCHEARTFAILURE.

270. Lopes C, Pereira T, Barra S. Cardiac resynchronization therapy in patients with atrial fibrillation: a meta-analysis. Rev Port Cardiol. 2014;33(11):717-25. doi:10.1016/j.repc.2014.05.008.

271. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail. 2013;1(6):500-7. doi:10.1016/j.jchf.2013.06.003.

272. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52(15):1239-46. doi:10.1016/j.jacc.2008.06.043.

273. Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2006;48(4):734-43. doi:10.1016/j.jacc.2006.03.056.

274. Ferreira AM, Adragão P, Cavaco DM, et al. Benefit of cardiac resynchronization therapy in atrial fibrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation. Europace. 2008;10(7):809-15. doi:10.1093/europace/eun135.

275. Orlov MV, Gardin JM, Slawsky M, et al. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation. Am Heart J. 2010;159(2):264-70. doi:10.1016/j.ahj.2009.11.012.

276. Doshi RN, Daoud EG, Fellows C, et al. PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005; 16(11):1160-5. doi:10.1111/j.1540-8167.2005.50062.x.

277. Brignole M, Gammage M, Puggioni E, et al. Optimal Pacing SITE (OPSITE) Study Investigators. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J. 2005;26(7):712-22. doi:10.1093/eurheartj/ehi069.

278. Brignole M, Botto GL, Mont L, et al. Predictors of clinical efficacy of ‘Ablate and Pace’ therapy in patients with permanent atrial fibrillation. Heart. 2012;98(4):297-302. doi:10.1136/heartjnl-2011-301069.

279. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin Electrophysiol. 2007;30Suppl 1: S23-30. doi:10.1111/j.1540-8159.2007.00598.x.

280. Höijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized crossover study. Europace. 2006;8(1):51-5. doi:10.1093/europace/euj014.

281. van Geldorp IE, Vernooy K, Delhaas T, et al. Beneficial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. Europace. 2010;12(2):223-9. doi:10.1093/europace/eup378.

282. Laurenzi F, Achilli A, Avella A, et al. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors. Pacing Clin Electrophysiol. 2007;30(9):1096-104. doi:10.1111/j.1540-8159.2007.00819.x.

283. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;103(9):1280-4. doi:10.1016/j.amjcard.2009.01.023.

284. Foley PW, Muhyaldeen SA, Chalil S, et al. Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure. Europace. 2009;11(4):495-501. doi:10.1093/europace/eup037.

285. Paparella G, Sciarra L, Capulzini L, et al. Long-term effects of upgrading to biventricular pacing: differences with cardiac resynchronization therapy as primary indication. Pacing Clinical Electrophysiology. 2010;33(7):841-9. doi:10.1111/j.1540-8159.2010.02701.x.

286. Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. European Journal of Heart Failure. 2014;16(11):1199-205. doi:10.1002/ejhf.143.

287. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. The New England Journal of Medicine. 2010;363(1):36-44. doi:10.1056/NEJMoa0909545.

288. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128(9):944-53. doi:10.1161/CIRCULATIONAHA.113.003042.

289. Jarman JW, Lascelles K, Wong T, et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. European Heart Journal. 2012;33(11):1351-9. doi:10.1093/eurheartj/ehs017.

290. Dabiri Abkenari L, Theuns DA, Valk SD, et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clinical Research in Cardiology. 2011;100(9):737-44. doi:10.1007/s00392-011-0303-6.

291. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. Journal of the American College of Cardiology. 2015;65(16):1605-15. doi:10.1016/j.jacc.2015.02.047.

292. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. European Heart Journal. 2014;35(25):1657-65. doi:10.1093/eurheartj/ehu112.

293. Irvine J, Dorian P, Baker B, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). American Heart Journal. 2002;144(2):282-9. doi:10.1067/mhj.2002.124049.

294. Tomzik J, Koltermann KC, Zabel M, et. Al. Quality of Life in Patients with an Implantable Cardioverter Defibrillator: A Systematic Review. Frontiers in Cardiovascular Medicine. 2015;2:34. doi:10.3389/fcvm.2015.00034.

295. Schron EB, Exner DV, Yao Q, et. Al. Quality of life in the antiarrhythmics versus implantable defibrillators trial impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105(5):589-94. doi:10.1161/hc0502.103330.

296. Koopman HM, Vrijmoet-Wiersma CM, Langius JN, et al. Psychological functioning and disease-related quality of life in pediatric patients with an implantable cardioverter defibrillator. Pediatric Cardiology. 2012;33(4):569-75. doi:10.1007/s00246-012-0175-1.

297. Padeletti L, Arnar DO, Boncinelli L, et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace. 2010;12(10):1480-9. doi:10.1093/europace/euq275.

298. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2009;11(5):433-43. doi:10.1093/eurjhf/hfp041.

299. Scott PA, Silberbauer J, McDonagh TA, Murgatroyd FD. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: a meta-analysis. Heart Rhythm. 2014;11(5):828-35. doi:10.1016/j.hrthm.2014.02.009.

300. Tan VH, Wilton SB, Kuriachan V, et al. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circulation: Arrhythmia and Electrophysiology. 2014;7(1):164-70. doi:10.1161/CIRCEP.113.001217.

301. Saeed M, Hanna I, Robotis D, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2014;25(1):52-9. doi:10.1111/jce.12273.

302. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110(17):2591-6. doi:10.1161/01.CIR.0000145610.64014.E4.

303. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 2005;111(22):2898-905. doi:10.1161/CIRCULATIONAHA.104.526673.

304. Borne RT, Varosy PD, Masoudi FA. Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med. 2013;173(10):859-65. doi:10.1001/jamainternmed.2013.428.

305. Berg SK, Higgins M, Reilly CM, et al. Sleep quality and sleepiness in persons with implantable cardioverter defibrillators: outcome from a clinical randomized longitudinal trial. Pacing Clin Electrophysiol. 2012;35(4):431-43. doi:10.1111/j.1540-8159.2011.03328.x.

306. Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367(24):2275-83. doi:10.1056/NEJMoa1211107.

307. Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309(18):1903-11. doi:10.1001/jama.2013.4598.

308. 308 Wilkoff BL, Cook JR, Epstein AE, et al.; Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288(24):3115-23. doi:10.1001/jama.288.24.3115.

309. Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52(7):541-50. doi:10.1016/j.jacc.2008.05.011.

310. Ploux S, Swerdlow CD, Strik M, et al. Towards eradication of inappropriate therapies for ICD lead failure by combining comprehensive remote monitoring and lead noise alerts. J Cardiovasc Electrophysiol. 2018;29(8):1125-34. doi:10.1111/jce.13653.

311. Ellenbogen KA, Gunderson BD, Stromberg KD, Swerdlow CD. Performance of Lead Integrity Alert to assist in the clinical diagnosis of implantable cardioverter defibrillator lead failures: analysis of different implantable cardioverter defibrillator leads. Circ Arrhythm Electrophysiol. 2013;6(6):1169-77. doi:10.1161/CIRCEP.113.000744.

312. Swerdlow CD, Gunderson BD, Ousdigian KT, et al. Downloadable software algorithm reduces inappropriate shocks caused by implantable cardioverter-defibrillator lead fractures: a prospective study. Circulation. 2010;122(15):1449-55. doi:10.1161/CIRCULATIONAHA.110.962407.

313. Guédon-Moreau L, Kouakam C, Klug D, et al. Decreased delivery of inappropriate shocks achieved by remote monitoring of ICD: a substudy of the ECOST trial. J Cardiovasc Electrophysiol. 2014;25(7):763-70. doi:10.1111/jce.12405.

314. Gulizia MM, Piraino L, Scherillo M, et al. A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators: the PITAGORA ICD trial. Circ Arrhythm Electrophysiol. 2009;2(2):146-53. doi:10.1161/CIRCEP.108.804211.

315. Silka MJ, Shah MJ, Silva JNA, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Executive Summary. Heart Rhythm. 2021;18(11):1925-50. doi:10.1016/j.hrthm.2021.07.051.

316. Gold MR, Weiss R, Theuns DA, et al. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014;11(8):1352-8. doi:10.1016/j.hrthm.2014.04.012.

317. Mesquita J, Cavaco D, Ferreira A, et al. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery. Int J Cardiol. 2017;232:176-80. doi:10.1016/j.ijcard.2017.01.034.

318. Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021;43(1):7-17. doi:10.1161/CIRCULATIONAHA.120.048728.

319. Gilliam FR, Hayes DL, Boehmer JP, et al. Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol. 2011;22(9):1023-9. doi:10.1111/j.1540-8167.2011.02086.x.

320. Hupcey JE, Kitko L, Alonso W. Patients’ Perceptions of Illness Severity in Advanced Heart Failure. J Hosp Palliat Nurs. 2016;18(2):110-4. doi:10.1097/NJH.0000000000000229.

321. Tsutsui H, Isobe M, Ito H, et al. Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure — Digest Version. Circ J. 2019;83(10):2084-184. doi:10.1253/circj.CJ-19-0342.

322. Lewis WR, Luebke DL, Johnson NJ, et al. Withdrawing implantable defibrillator shock therapy in terminally ill patients. Am J Med. 2006;119(10):892-6. doi:10.1016/j.amjmed.2006.01.017.

323. Goldstein NE, Lampert R, Bradley E, et al. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med. 2004;141(11):835-8. doi:10.7326/0003-4819-141-11-200412070-00006.

324. Kinch Westerdahl A, Sjöblom J, Mattiasson AC, et al. Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life. Circulation. 2014;129(4):422-9. doi:10.1161/CIRCULATIONAHA.113.002648.

325. Brady DR. Planning for Deactivation of Implantable Cardioverter Defibrillators at the End of Life in Patients With Heart Failure. Crit Care Nurse. 2016;36(6):24-31. doi:10.4037/ccn2016362.

326. Ferrell BR, Twaddle ML, Melnick A, Meier DE. National Consensus Project Clinical Practice Guidelines for Quality Palliative Care Guidelines, 4th Edition. J Palliat Med. 2018; 21(12):1684-9.

327. Stoevelaar R, Brinkman-Stoppelenburg A, van Driel AG, et al. Trends in time in the management of the implantable cardioverter defibrillator in the last phase of life: a retrospective study of medical records. Eur J Cardiovasc Nurs. 2019;18(6):449-57. doi:10.1177/1474515119844660.

328. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505-35. doi:10.1002/ejhf.1236.

329. Kida K, D o i S, Suzuki N. Palliative Care in Patients with Advanced Heart Failure. Heart Fail Clin. 2020;16(2):243-54. doi:10.1016/j.hfc.2019.12.006.

330. Lowey SE. Palliative Care in the Management of Patients with Advanced Heart Failure. Adv Exp Med Biol. 2018;1067:295-311. doi:10.1007/5584_2017_115.

331. Гасымова Н.З., Шабанов В.В., Сафонов Н.В. и др. Многоконтактное картирование в лечении различных нарушений ритма сердца. Вестник аритмологии. 2024;31(1):110-22. doi:10.35336/VA-1297.

332. Philip Saul J, Kanter RJ; WRITING COMMITTEE; PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease. Heart Rhythm. 2016;13(6):e251-89. doi:10.1016/j.hrthm.2016.02.009.

333. Crosson JE, Callans DJ, Bradley DJ, et al. PACES/HRS expert consensus statement on the evaluation and management of ventricular arrhythmias in the child with a structurally normal heart. Heart Rhythm. 2014;11(9):e55-78. doi:10.1016/j.hrthm.2014.05.010.

334. Latchamsetty R, Bogun F. Premature Ventricular Complexes and Premature Ventricular Complex Induced Cardiomyopathy. Current Problems in Cardiology. 2015;40(9):379-422. doi:10.1016/j.cpcardiol.2015.03.002.

335. Daniels DV, Lu YY, Morton JB, et al Idiopathic epicardial left ventricular tachycardia originating remote from the sinus of Valsalva: electrophysiological characteristics, catheter ablation, and identification from the 12-1ead electrocardiogram. Circulation. 2006;113(13):1659-66. doi:10.1161/CIRCULATIONAHA.105.611640.

336. Doppalapudi H, Yamada T, McElderry HT, et al. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. Circulation: Arrhythmia and Electrophysiology. 2008;1(1):23-9. doi:10.1161/CIRCEP.107.742940.

337. Sapp JL, Tang ASL, Parkash R, et al. A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial. Am. Heart J. 2024;274:1-10. doi:10.1016/j.ahj.2024.04.009.

338. Visser CA, Kan G, David GK, et al. Two dimensional echocardiography in the diagnosis of left ventricular thrombus: a prospective study of 67 patients with anatomic validation. Chest. 1983;83(2):228-32. doi:10.1378/chest.83.2.228.

339. Weinsaft JW, Kim RJ, Ross M, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovascular Imaging. 2009;2(8):969-79. doi:10.1016/j.jcmg.2009.03.017.

340. Soto-Iglesias D, Acosta J, Penela D, et al. Image-based criteria to identify the presence of epicardial arrhythmogenic substrate in patients with transmural myocardial infarction. Heart Rhythm. 2018;15(6):814-21. doi:10.1016/j.hrthm.2018.02.007.

341. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. The New England Journal of Medicine. 2007;357(26):2657-65. doi:10.1056/NEJMoa065457.

342. Kumar S, Baldinger SH, Romero J, et al. Substrate-based ablation versus ablation guided by activation and entrainment mapping for ventricular tachycardia: a systematic review and meta-analysis. Journal of Cardiovascular Electrophysiology. 2016;27(12):1437-47. doi:10.1111/jce.13088.

343. Acosta J, Penela D, Andreu D, et al. Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace. 2018;20(3):512-9. doi:10.1093/europace/euw406.

344. Berte B, Relan J, Sacher F, et al. Impact of electrode type on mapping of scar-related VT. Journal of Cardiovascular Electrophysiology. 2015;26(11):1213-23. doi:10.1111/jce.12761.

345. Yamashita S, Cochet H, Sacher F, et al. Impact of new technologies and approaches for post-myocardial infarction ventricular tachycardia ablation during long-term follow-up. Circulation: Arrhythmia and Electrophysiology. 2016;9(7):e003901. doi:10.1161/CIRCEP.116.003901.

346. Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circulation: Arrhythmia and Electrophysiology. 2013;6(5):891-7. doi:10.1161/CIRCEP.113.000073.

347. Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9(9):1465-72. doi:10.1016/j.hrthm.2012.05.019.

348. Winbo A, Paterson DJ. The Brain-Heart Connection in Sympathetically Triggered Inherited Arrhythmia Syndromes. Heart Lung Circ. 2020;29(4):529-37. doi:10.1016/j.hlc.2019.11.002.

349. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109(15):1826-33. doi:10.1161/01.CIR.0000125523.14403.1E.

350. Ataklte F, Erqou S, Laukkanen J, Kaptoge S. Meta-analysis of ventricular premature complexes and their relation to cardiac mortality in general populations. Am J Cardiol. 2013;112(8):1263-70. doi:10.1016/j.amjcard.2013.05.065.

351. Arnar DO, Mairesse GH, Boriani G, et al. Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). Europace. 2019;21(6):844-45. doi:10.1093/europace/euz046.

352. Lee V, Perera D, Lambiase P. Prognostic significance of exercise-induced premature ventricular complexes: a systematic review and meta-analysis of observational studies. Heart Asia. 2017;9(1):14-24. doi:10.1136/heartasia-2016-010854.

353. Lin CY, Chang SL, Chung FP, et al. Long-Term Outcome of Non-Sustained Ventricular Tachycardia in Structurally Normal Hearts. PLoS One. 2016;11(8):e0160181. doi:10.1371/journal.pone.0160181.

354. Muser D, Nucifora G, Muser D, et al. Prognostic Value of Nonischemic Ringlike Left Ventricular Scar in Patients With Apparently Idiopathic Nonsustained Ventricular Arrhythmias. Circulation. 2021;143(14):1359-73. doi:10.1161/CIRCULATIONAHA.120.047640.

355. Aquaro GD, Pingitore A, Strata E, et al. Cardiac magnetic resonance predicts outcome in patients with premature ventricular complexes of left bundle branch block morphology. J Am Coll Cardiol. 2010;56(15):1235-43. doi:10.1016/j.jacc.2010.03.087.

356. Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95(15):1230-7. doi:10.1136/hrt.2008.159558.

357. Sharma N, Cortez D, Imundo JR. High burden of premature ventricular contractions in structurally normal hearts: To worry or not in pediatric patients? Ann Noninvasive Electrocardiol. 2019;24(6):e12663. doi:10.1111/anec.12663.

358. Hamon D, Swid MA, Rajendran PS, et al. Premature ventricular contraction diurnal profiles predict distinct clinical characteristics and beta-blocker responses. J Cardiovasc Electrophysiol. 2019;30(6):836-43. doi:10.1111/jce.13944.

359. Чуева К. А., Татарский Р. Б., Ковальчук Т. С. и др. Возможности магнитно-резонансной томографии в поиске субстрата "идиопатических" желудочковых аритмий у детей. Вестник аритмологии. 2021;28(4):9-14.

360. Prystowsky EN, Padanilam BJ, Joshi S, Fogel RI. Ventricular arrhythmias in the absence of structural heart disease. J Am Coll Cardiol. 2012;59(20):1733-44. doi:10.1016/j.jacc.2012.01.036.

361. Pfammatter JP, Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coll Cardiol. 1999;33(7):2067-72. doi:10.1016/s0735-1097(99)00105-9.

362. Kjekshus J, Bathen J, Orning OM, Storstein L. A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol. 1984;53(5):72B-78B. doi:10.1016/0002-9149(84)90506-x.

363. Krittayaphong R, Sriratanasathavorn C, Dumavibhat C, et al. Electrocardiographic predictors of long-term outcomes after radiofrequency ablation in patients with right-ventricular outflow tract tachycardia. Europace. 2006;8(8):601-6. doi:10.1093/europace/eul067.

364. Komatsu Y, Nogami A, Kurosaki K, et al. Fascicular Ventricular Tachycardia Originating From Papillary Muscles: Purkinje Network Involvement in the Reentrant Circuit. Circ Arrhythm Electrophysiol. 2017;10(3):e004549. doi:10.1161/CIRCEP.116.004549.

365. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77-82. doi:10.1056/NEJM199507133330201.

366. Callans DJ, Menz V, Schwartzman D, et al. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol. 1997;29(5):1023-7. doi:10.1016/s0735-1097(97)00004-1.

367. Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular tachycardias arising from the aortic sinus of valsalva: an under-recognized variant of left outflow tract ventricular tachycardia. J Am Coll Cardiol. 2001;37(5):1408-14. doi:10.1016/s0735-1097(01)01127-5.

368. van Huls van Taxis CF, Piers SR, de Riva Silva M, et al. Fatigue as Presenting Symptom and a High Burden of Premature Ventricular Contractions Are Independently Associated With Increased Ventricular Wall Stress in Patients With Normal Left Ventricular Function. Circ Arrhythm Electrophysiol. 2015;8(6):1452-9. doi:10.1161/CIRCEP.115.003091.

369. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. 2007;4(7):863-7. doi:10.1016/j.hrthm.2007.03.003.

370. Lee A, Denman R, Haqqani HM. Ventricular Ectopy in the Context of Left Ventricular Systolic Dysfunction: Risk Factors and Outcomes Following Catheter Ablation. Heart Lung Circ. 2019;28(3):379-88. doi:10.1016/j.hlc.2018.01.012.

371. Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm. 2011;8(10):1608-14. doi:10.1016/j.hrthm.2011.04.026.

372. Penela D, Van Huls Van Taxis C, Aguinaga L, et al. Neurohormonal, structural, and functional recovery pattern after premature ventricular complex ablation is independent of structural heart disease status in patients with depressed left ventricular ejection fraction: a prospective multicenter study. J Am Coll Cardiol. 2013;62(13):1195-202. doi:10.1016/j.jacc.2013.06.012.

373. Zang M, Zhang T, Mao J, et al. Beneficial effects of catheter ablation of frequent premature ventricular complexes on left ventricular function. Heart. 2014;100(10):787-93. doi:10.1136/heartjnl-2013-305175.

374. Jabbari R, Engstrøm T, Glinge C, et al. Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: a nationwide study in Denmark. J Am Heart Assoc. 2015;4(1):e001399. doi:10.1161/JAHA.114.001399.

375. Orvin K, Eisen A, Goldenberg I, et al. Outcome of contemporary acute coronary syndrome complicated by ventricular tachyarrhythmias. Europace. 2016;18(2):219-26. doi:10.1093/europace/euv027.

376. Demirel F, Rasoul S, Elvan A, et al. Impact of out-of-hospital cardiac arrest due to ventricular fibrillation in patients with ST-elevation myocardial infarction admitted for primary percutaneous coronary intervention: Impact of ventricular fibrillation in STEMI patients. Eur Heart J Acute Cardiovasc Care. 2015;4(1):16-23. doi:10.1177/2048872614547448.

377. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301(17):1779-89. doi:10.1001/jama.2009.600.

378. Demidova MM, Carlson J, Erlinge D, Platonov PG. Predictors of ventricular fibrillation at reperfusion in patients with acute ST-elevation myocardial infarction treated by primary percutaneous coronary intervention. The American Journal of Cardiology. 2015;115(4):417-22. doi:10.1016/j.amjcard.2014.11.025.

379. Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv. 2010;3(3):200-7. doi:10.1161/CIRCINTERVENTIONS.109.913665.

380. Cheng Y-J, Li Z-Y, Yao F-J, et al. Early repolarization is associated with a significantly increased risk of ventricular arrhythmias and sudden cardiac death in patients with structural heart disease. Heart Rhythm. 2017;14(8):1157-64. doi:10.1016/j.hrthm.2017.04.022.

381. Dumas F, Bougouin W, Geri G, et al. Emergency percutaneous coronary intervention in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry. JACC. 2016;9(10):1011-8. doi:10.1016/j.jcin.2016.02.001.

382. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.

383. Chatterjee S, Chaudhuri D, Vedanthan R, et al. Early intravenous beta-blockers in patients with acute coronary syndrome — a meta-analysis of randomized trials. International Journal of Cardiology. 2013;168(2):915-21. doi:10.1016/j.ijcard.2012.10.050.

384. Windecker S, Koth P, Alfonso F, et al. 2014 ЕОК/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ЕОК) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541-619. doi:10.1093/eurheartj/ehu278.

385. Roffi M, Patrono C, Cotter JP, et al. 2015 ЕОК Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. European Heart Journal. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.

386. Steg PG, James SK, Atar D, et al. ЕОК Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012;33(20):2569-619. doi:10.1093/eurheartj/ehs215.

387. Soholm H, Wachte UK, Nietsen SL, et al. Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest. Resuscitation. 2013;84(2):162-7. doi:10.1016/j.resuscitation.2012.06.029.

388. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348(9030):771-5. doi:10.1016/S0140-6736(96)02514-7.

389. Boersma E. Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. European Heart Journal. 2006;27(7):779-88. doi:10.1093/eurheartj/ehi810.

390. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367(9510):579-88. doi:10.1016/S0140-6736(06)68148-8.

391. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. The New England Journal of Medicine. 1997;336(23):1629-33. doi:10.1056/NEJM199706053362302.

392. Bowers TR, O’Neitt WW, Grines C, et al. Effect of reperfusion on biventricular function and survival after right ventricular infarction. The New England Journal of Medicine. 1998;338(14):933-40. doi:10.1056/NEJM199804023381401.

393. Gorenek B, Blomstrom Lundqvist C, Brugada P, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EH RA, ACCA, and EAPCI task force. Europace. 2015;4(4):386. doi:10.1177/2048872614550583.

394. Piccini JP, Hranitzky PM, Kilaru R, et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol. 2008;102(11):1427-32. doi:10.1016/j.amjcard.2008.07.033.

395. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345(20):1473-82. doi:10.1056/NEJMra000650.

396. Bougouin W, Marijon E, Puymirat E, et al. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J. 2014;35(2):116-22. doi:10.1093/eurheartj/eht453.

397. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102(7):742-7. doi:10.1161/01.cir.102.7.742.

398. Piccini JP, Schulte PJ, Pieper KS, et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med. 2011;39(1):78-83. doi:10.1097/CCM.0b013e3181fd6ad7.

399. Malik M, Camm AJ, Janse MJ, et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol. 2000;35(5):1263-75. doi:10.1016/s0735-1097(00)00571-4.

400. Ahn JM, Lee KH, Yoo SY, et al. Prognosis of Variant Angina Manifesting as Aborted Sudden Cardiac Death. J Am Coll Cardiol. 2016;68(2):137-45. doi:10.1016/j.jacc.2016.04.050.P.

401. Sueda S, Kohno H. Optimal Medications and Appropriate Implantable Cardioverter-defibrillator Shocks in Aborted Sudden Cardiac Death Due to Coronary Spasm. Intern Med. 2018;57(10):1361-9. doi:10.2169/internalmedicine.8796-17.

402. Rodríguez-Mañero M, Oloriz T, et al. Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm. Europace. 2018;20(5):851-8. doi:10.1093/europace/eux052.

403. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000;342(26):1937-45. doi:10.1056/NEJM200006293422602.

404. Exner DV, Kavanagh KM, Slawnych MP, et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol. 2007;50(24):2275-84. doi:10.1016/j.jacc.2007.08.042.

405. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151-8. doi:10.1016/s0735-1097(02)01726-6.

406. Altmann DR, Mutschelknauss M, Ehl N, et al. Prevalence of severely impaired left ventricular ejection fraction after reperfused ST-elevation myocardial infarction. Swiss Med Wkly. 2013;143:w13869. doi:10.4414/smw.2013.13869.

407. Shen L, Jhund PS, Petrie MC, et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017;377(1):41-51. doi:10.1056/NEJMoa1609758.

408. Gatzoulis KA, Tsiachris D, Arsenos P, et al. Prognostic value of programmed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J Cardiol. 2014;.176(3):1449-51. doi:10.1016/j.ijcard.2014.08.068.

409. Olshansky B, Hahn EA, Hartz VL, et al. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. The ESVEM Investigators. Am Heart J. 1999;137(5):878-86. doi:10.1016/s0002-8703(99)70412-6.

410. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-83. doi:10.1056/NEJM199711273372202.

411. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d, l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340(24):1855-62. doi:10.1056/NEJM199906173402402.

412. Kuck KH, Schaumann A, Eckardt L, et al. VTACH study group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375(9708):31-40. doi:10.1016/S0140-6736(09)61755-4.

413. Willems S, Tilz RR, Steven D, et al. BERLIN VT Investigators. Preventive or Deferred Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT): A Multicenter Randomized Trial. Circulation. 2020;141(13):1057-67. doi:10.1161/CIRCULATIONAHA.119.043400.

414. Kuck KH, Tilz RR, Deneke T, et al. SMS Investigators. Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter-Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results From the Multicenter Randomized Controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017;10(3):e004422. doi:10.1161/CIRCEP.116.004422.

415. Pitt B, White H, Nicolau J, et al. EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425-31. doi:10.1016/j.jacc.2005.04.038.

416. Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter-defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of >35,000 patients. Int J Cardiol. 2014;173(2):197-203. doi:10.1016/j.ijcard.2014.02.014.

417. Chatterjee S, Udell JA, Sardar P, et al. Comparable benefit of β-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. Can J Cardiol. 2014;30(8):898-903. doi:10.1016/j.cjca.2014.03.012.

418. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394.

419. Dor V, Civaia F, Alexandrescu C, et al. Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2011;141(4):905-16. doi:10.1016/j.jtcvs.2010.10.026.

420. Jones RH, Velazquez EJ, Michler RE, et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360(17):1705-17. doi:10.1056/NEJMoa0900559.

421. Babokin V, Shipulin V, Batalov R, Popov S. Surgical ventricular reconstruction with endocardectomy along radiofrequency ablation-induced markings. J Thorac Cardiovasc Surg. 2013;146(5):1133-8. doi:10.1016/j.jtcvs.2012.08.067.

422. Sartipy U, Albåge A, Insulander P, Lindblom D. Surgery for ventricular tachycardia in patients undergoing surgical ventricular restoration: the Karolinska approach. J Interv Card Electrophysiol. 2007;19(3):171-8. doi:10.1007/s10840-007-9152-7.

423. Bayés de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989;117(1):151-9. doi:10.1016/0002-8703(89)90670-4.

424. Josephson ME, Harken AH, Horowitz LN. Endocardial excision: a new surgical technique for the treatment of recurrent ventricular tachycardia. Circulation. 1979;60(7):1430-9. doi:10.1161/01.cir.60.7.1430.

425. Reddy YM, Chinitz L, Mansour M, et al. Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. Circ Arrhythm Electrophysiol. 2014;7(2):244-50. doi:10.1161/CIRCEP.113.000548.

426. Dor V, Sabatier M, Montiglio F, et al. Results of nonguided subtotal endocardiectomy associated with left ventricular reconstruction in patients with ischemic ventricular arrhythmias. J Thorac Cardiovasc Surg. 1994;107(5):1301-7.

427. Molossi S, Agrawal H, Mery CM, et al. Outcomes in anomalous aortic origin of a coronary artery following a prospective standardized approach. Circulation: Cardiovascular Interventions. 2020;13(2):e008445. doi:10.1161/CIRCINTERVENTIONS.119.008445.

428. Krasuski RA, Magyar D, Hart S, et al. Long-term outcome and impact of surgery on adults with coronary arteries originating from the opposite coronary cusp. Circulation. 2011;123(2):154-62. doi:10.1161/CIRCULATIONAHA.109.921106.

429. Jegatheeswaran A, Devlin PJ, McCrindle BW, et al. Features associated with myocardial ischemia in anomalous aortic origin of a coronary artery: a congenital heart surgeons’ society study. The Journal of Thoracic and Cardiovascular Surgery. 2019;158(3):822-34. doi:10.1016/j.jtcvs.2019.02.122.

430. Jegatheeswaran A, Devlin PJ, Williams WG, et al. Outcomes after anomalous aortic origin of a coronary artery repair: a congenital heart surgeons’ society study. The Journal of Thoracic and Cardiovascular Surgery. 2020;160(3):757-71. doi:10.1016/j.jtcvs.2020.01.114.

431. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2008;29(2):270-6. doi:10.1093/eurheartj/ehm342.

432. Ader F, De Groote P, Réant P, et al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations. Clinical Genetics. 2019;96(4):317-29. doi:10.1111/cge.13594.

433. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. JACC. 2016;68(22):2440-51. doi:10.1016/j.jacc.2016.09.927.

434. Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. JACC. 2019;74(11):1480-90. doi:10.1016/j.jacc.2019.06.072.

435. Van den Hoogenhof MMG, Beqqali A, Amin AS, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy related to disturbed calcium handling. Circulation. 2018;138(13):1330-42. doi:10.1161/CIRCULATIONAHA.117.031947.

436. Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals. Clinical Research in Cardiology. 2017;106(2):127-39. doi:10.1007/s00392-016-1033-6.

437. Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC. 2017;5(1):28-38. doi:10.1016/j.jchf.2016.09.017.

438. Francone M. Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance. ISRN Radiology. 2014;365404. doi:10.1155/2014/365404.

439. Klem I, Klein M, Khan M, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation. 2021;143(14):1343-58. doi:10.1161/CIRCULATIONAHA.120.048477.

440. Goldberger JJ, Subačius H, Patel T, et al. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. JACC. 2014;63(18):1879-89. doi:10.1016/j.jacc.2013.12.021.

441. Link MS, Costeas XF, Griffith JL, et al. High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. JACC. 1997;29(2):370-5. doi:10.1016/s0735-1097(96)00477-9.

442. Thuillot M, Maupain C, Gandjbakhch E, et al. External validation of risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. Eur J Heart Fail. 2019;21(2):253-4. doi:10.1002/ejhf.1384.

443. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997;350(9089):1417-24.

444. Skjølsvik ET, Hasselberg NE, Dejgaard LA, et al. Exercise is Associated With Impaired Left Ventricular Systolic Function in Patients With Lamin A/C Genotype. J Am Heart Assoc. 2020;9(2):e012937. doi:10.1161/JAHA.119.012937.

445. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-12. doi:10.1056/NEJM198908103210629.

446. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-76. doi:10.1056/NEJMoa1109867.

447. Beggs SAS, Jhund PS, Jackson CE, et al. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart. 2018;104(2):144-150. doi:10.1136/heartjnl-2016-310850.

448. Zabel M, Willems R, Lubinski A, et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020;41(36):3437-47. doi:10.1093/eurheartj/ehaa226.

449. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59(5):493-500. doi:10.1016/j.jacc.2011.08.078.

450. Di Marco A, Brown PF, Bradley J, et al. Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy. J Am Coll Cardiol. 2021;77(23):2890-905. doi:10.1016/j.jacc.2021.04.030.

451. Merlo M, Gentile P, Artico J, et al. Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction. J Cardiovasc Med (Hagerstown). 2019;20(5):343-50. doi:10.2459/JCM.0000000000000792.

452. Mariani MV, Pierucci N, Fanisio F. Inherited Arrhythmias in the Pediatric Population: An Updated Overview. Medicina (Kaunas). 2024;60(1):94. doi:10.3390/medicina60010094.

453. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071-8. doi:10.1053/euhj.2000.2476.

454. Dinov B, Fiedler L, Schönbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129(7):728-36. doi:10.1161/CIRCULATIONAHA.113.003063.

455. Ebert M, Wijnmaalen AP, de Riva M, et al. Prevalence and Prognostic Impact of Pathogenic Variants in Patients With Dilated Cardiomyopathy Referred for Ventricular Tachycardia Ablation. JACC Clin Electrophysiol. 2020;6(9):1103-14. doi:10.1016/j.jacep.2020.04.025.

456. Muser D, Santangeli P, Castro SA, et al. Long-Term Outcome After Catheter Ablation of Ventricular Tachycardia in Patients With Nonischemic Dilated Cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9(10):e004328. doi:10.1161/CIRCEP.116.004328.

457. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12(9):1997-2007. doi:10.1016/j.hrthm.2015.05.036.

458. Corrado D, Link MS, Calkins H. Arrhythmogenic Right Ventricular Cardiomyopathy. N Engl J Med. 2017;376(15):1489-90. doi:10.1056/NEJMc1701400.

459. Aquaro GD, Barison A, Todiere G, et al. Usefulness of Combined Functional Assessment by Cardiac Magnetic Resonance and Tissue Characterization Versus Task Force Criteria for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy. Am J Cardiol. 2016;118(11):1730-6. doi:10.1016/j.amjcard.2016.08.056.

460. Rastegar N, Te Riele AS, James CA, et al. Fibrofatty Changes: Incidence at Cardiac MR Imaging in Patients with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Radiology. 2016;280(2):405-12. doi:10.1148/radiol.2016150988.

461. te Riele AS, Bhonsale A, James CA, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(19):1761-9. doi:10.1016/j.jacc.2012.11.087.

462. Cicenia M, Drago F. Arrhythmogenic Cardiomyopathy: Diagnosis, Evolution, Risk Stratification and Pediatric Population-Where Are We? J Cardiovasc Dev Dis. 2022;9(4):98. doi:10.3390/jcdd9040098.

463. Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36(14):847-55. doi:10.1093/eurheartj/ehu509.

464. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6(6):533-42. doi:10.1161/CIRCGENETICS.113.000288.

465. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58(14):1485-96. doi:10.1016/j.jacc.2011.06.043.

466. Saguner AM, Medeiros-Domingo A, Schwyzer MA, et al. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2013;111(2):250-7. doi:10.1016/j.amjcard.2012.09.025.

467. Chivulescu M, Lie ØH, Popescu BA, et al. High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy. Eur Heart J. 2020;41(14):1401-10. doi:10.1093/eurheartj/ehz570.

468. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(14):1290-7. doi:10.1016/j.jacc.2013.06.033.

469. Lie ØH, Dejgaard LA, Saberniak J, et al. Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy. JACC Clin Electrophysiol. 2018;4(6):744-53. doi:10.1016/j.jacep.2018.01.010.

470. Saberniak J, Hasselberg NE, Borgquist R, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail. 2014;16(12):1337-44. doi:10.1002/ejhf.181.

471. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16(11):e301-e372. doi:10.1016/j.hrthm.2019.05.007.

472. Te Riele ASJM, James CA, Calkins H, Tsatsopoulou A. Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity. Front Pediatr. 2021;9:750916. doi:10.3389/fped.2021.750916.

473. Sawant AC, Te Riele AS, Tichnell C, et al. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016;13(1):199-207. doi:10.1016/j.hrthm.2015.08.035.

474. Denis A, Sacher F, Derval N, et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2014;7(4):590-7. doi:10.1161/CIRCEP.113.001224.

475. Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. JACC. 2009;54(7):609-15. doi:10.1016/j.jacc.2009.04.052.

476. Canpolat U, Aytemir K, Dural M, et al. Fragmented QRS complex predicts the arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: frQRS and outcomes in ARVC/D/Journal of Cardiovascular Electrophysiology. 2013;24(11):1260-6. doi:10.1111/jce.12202.

477. Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122(12):1144-52. doi:10.1161/CIRCULATIONAHA.109.913871.

478. Martin A, Crawford J, Skinner JR, Smith W. High arrhythmic burden but low mortality during long-term follow-up in arrhythmogenic right ventricular cardiomyopathy. Heart, Lung and Circulation. 2016;25(3):275-81. doi:10.1016/j.hlc.2015.08.019.

479. Mazzanti A, Ng K, Faragli A, et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. JACC. 2016;68(23):2540-50. doi:10.1016/j.jacc.2016.09.951.

480. Santangeli P, Dello Russo A, Pieroni M, et al. Fragmented and delayed electrograms within fibrofatty scar predict arrhythmic events in arrhythmogenic right ventricular cardiomyopathy: Results from a prospective risk stratification study. Heart Rhythm. 2012;9(8):1200-6. doi:10.1016/j.hrthm.2012.03.057.

481. Hulot J-S, Jouven X, Empana J-P, et al. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004;110(14):1879-84. doi:10.1161/01.CIR.0000143375.93288.82.

482. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/ dysplasia. Circulation. 2003;108(25):3084-91. doi:10.1161/01.CIR.0000103130.33451.D2.

483. Wang W, Cadrin-Tourigny J, Bhonsale A, et al. Arrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients without implantable defibrillators. Journal of Cardiovascular Electrophysiology. 2018;29(10):1396-402. doi:10.1111/jce.13668.

484. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. JACC. 2014;64(2):119-25. doi:10.1016/j.jacc.2014.04.035.

485. Mahida S, Venlet J, Saguner AM, et al. Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: results from a multicenter study. Heart Rhythm. 2019;16(4):536-43. doi:10.1016/j.hrthm.2018.10.016.

486. Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ: Arrhythmia and Electrophysiology. 2015;8(6):1413-21. doi:10.1161/CIRCEP.115.003562.

487. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic сardiomyopathy: executive summary: a report of the American College of Cardiology. American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e533-e557. doi:10.1161/CIR.0000000000000938.

488. Lorenzini M, Anastasiou Z, O’Mahony C, et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiology. 2020;5(1):73-80. doi:10.1001/jamacardio.2019.4534.

489. O’Mahony C, Jichi F, Ommen SR, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137(10):1015-23. doi:10.1161/CIRCULATIONAHA.117.030437.

490. Vriesendorp PA, Schinkel AF, Liebregts M, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829-35. doi:10.1161/CIRCEP.114.002553.

491. O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010-20. doi:10.1093/eurheartj/eht439.

492. Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484-95. doi:10.1161/CIRCULATIONAHA.113.007094.

493. Smith BM, Dorfman AL, Yu S, et al. Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy. Am J Cardiol. 2014;113(7):1234-9. doi:10.1016/j.amjcard.2013.12.034.

494. Miron A, Lafreniere-Roula M, Steve Fan CP, et al. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation. 2020;142(3):217-29. doi:10.1161/CIRCULATIONAHA.

495. He D, Ye M, Zhang L, Jiang B. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart Lung. 2018;47(2):122-6. doi:10.1016/j.hrtlng.2017.10.008.

496. Weissler-Snir A, Dorian P, Rakowski H, et al. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy? Heart Rhythm. 2021;18(1):63-70. doi:10.1016/j.hrthm.2020.08.009.

497. Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-98. doi:10.1161/CIRCULATIONAHA.117.033200.

498. Kim HY, Park JE, Lee SC, et al. Genotype-Related Clinical Characteristics and Myocardial Fibrosis and their Association with Prognosis in Hypertrophic Cardiomyopathy. J Clin Med. 2020;9(6):1671. doi:10.3390/jcm9061671.

499. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm. 2012;9(1):57-63. doi:10.1016/j.hrthm.2011.08.009.

500. Rosmini S, Biagini E, O’Mahony C, et al. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. Heart. 2017;103(4):300-6. doi:10.1136/heartjnl-2016-310138.

501. Wang J, Wang Y, Zou Y, et al. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail. 2014;16(9):950-7. doi:10.1002/ejhf.144.

502. Pelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26(14):1422-45. doi:10.1093/eurheartj/ehi325.

503. Национальные Рекомендации по определению риска и профилактике внезапной сердечной смерти (2-е издание). Шляхто Е. В., Арутюнов Г. П., Беленков Ю. Н. и др. М.: ИД "Медпрактика-М", 2018, 247 с. ISBN: 978-5-98803-397-4.

504. Norrish G, Ding T, Field E, et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiol. 2019;4(9):918-27. doi:10.1001/jamacardio.2019.2861.

505. Norrish G, Qu C, Field E, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2022;29(4):678-86. doi:10.1093/eurjpc/zwab181.

506. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212-8. doi:10.1016/s0735-1097(00)01003-2.

507. Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol. 2020; 75(24):3033-43. doi:10.1016/j.jacc.2020.04.045.

508. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017;69(7):761-73. doi:10.1016/j.jacc.2016.11.063. Erratum in: J Am Coll Cardiol. 2017;69(12):1652. doi:10.1016/j.jacc.2017.02.014.

509. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96(9):2987-91. doi:10.1161/01.cir.96.9.2987.

510. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol. 1989;13(6):1283-8. doi:10.1016/0735-1097(89)90302-1.

511. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33(6): 1596-601. doi:10.1016/s0735-1097(99)00056-x.

512. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405-12. doi:10.1001/jama.298.4.405.

513. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985;53(4):412-6. doi:10.1136/hrt.53.4.412.

514. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007;93(6):708-10. doi:10.1136/hrt.2006.099416.

515. Dukkipati SR, d’Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(2):185-94. doi:10.1161/CIRCEP.110.957290.

516. Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency Catheter Ablation of Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy and Apical Aneurysm. JACC Clin Electrophysiol. 2018;4(3):339-50. doi:10.1016/j.jacep.2017.12.020.

517. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5(2):235-40. doi:10.1016/j.hrthm.2007.10.016.

518. Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: Developed in collaboration with and endorsed by the Heart Rhythm Society (HRS), the American College of Cardiology (ACC), the American Heart Association (AHA), and the Association for European Paediatric and Congenital Cardiology (AEPC). Endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhythm Society (LAHRS). Cardiology in the Young. 2021;31(11):1738-69. doi:10.1017/S1047951121003413.

519. Bucci E, Testa M, Licchelli L, et al. A 34-year longitudinal study on long-term cardiac out-comes in DM1 patients with normal ECG at baseline at an Italian clinical centre. J Neurol. 2018;265(4):885-95. doi:10.1007/s00415-018-8773-3.

520. Breton R, Mathieu J. Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy. Can J Cardiol. 2009;25(2):e23-7. doi:10.1016/s0828-282x(09)70479-9.

521. Fayssoil A, Abasse S, Silverston K. Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2017;4(1):17-23. doi:10.3233/JND-160194.

522. Bhakta D, Groh MR, Shen C, et al. Increased mortality with left ventricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J. 2010;160(6):1137-41. doi:10.1016/j.ahj.2010.07.032.

523. Merino JL, Carmona JR, Fernández-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation. Circulation. 1998;98(6):541-6. doi:10.1161/01.cir.98.6.541.

524. Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA. 2012;307(12):1292-301. doi:10.1001/jama.2012.346.

525. Sanna T, Dello Russo A, Toniolo D, et al. Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutations. Eur Heart J. 2003;24(24):2227-36. doi:10.1016/j.ehj.2003.09.020.

526. Menon SC, Etheridge SP, Liesemer KN, et al. Predictive value of myocardial delayed enhancement in Duchenne muscular dystrophy. Pediatr Cardiol. 2014;35(7):1279-85. doi:10.1007/s00246-014-0929-z.

527. Prystowsky EN, Pritchett EL, Roses AD, Gallagher J. The natural history of conduction system disease in myotonic muscular dystrophy as determined by serial electrophysiologic studies. Circulation. 1979;60(6):1360-4. doi:10.1161/01.cir.60.6.1360.

528. Rajdev A, Groh WJ. Arrhythmias in the muscular dystrophies. Card Electrophysiol Clin. 2015;7(2):303-8. doi:10.1016/j.ccep.2015.03.011.

529. Shah Z, Mohammed M, Vuddanda V, Ansari MW. National trends, gender, management, and outcomes of patients hospitalized for myocarditis. The American Journal of Cardiology. 2019;124(1):131-6. doi:10.1016/j.amjcard.2019.03.036.

530. Rosier L, Zouaghi A, Barré V, et al. High risk of sustained ventricular arrhythmia recurrence after acute myocarditis. Journal of Clinical Medicine. 2020;9(3):848. doi:10.3390/jcm9030848.

531. Vaseghi M, Hu TY, Tung R, et al. Outcomes of catheter ablation of ventricular tachycardia based on etiology in nonischemic heart disease: an international ventricular tachycardia ablation center collaborative study. JACC. 2018;4(9):1141-50. doi:10.1016/j.jacep.2018.05.007.

532. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624-32. doi:10.1161/CIRCULATIONAHA.114.011522.

533. Nordenswan H-K, Lehtonen J, Ekström K, et al. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circulation: Arrhythmia and Electrophysiology. 2018;11(8):e006145. doi:10.1161/CIRCEP.117.006145.

534. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC. 2013;6(4):501-11. doi:10.1016/j.jcmg.2012.10.021.

535. Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ: Arrhythmia and Electrophysiology. 2011;4(1):43-8. doi:10.1161/CIRCEP.110.958322.

536. Robinson ML, Kobayashi T, Higgins Y, et al. Lyme carditis. Infectious Disease Clinics of North America. 2015;29(2):255-68. doi:10.1016/j.idc.2015.02.003.

537. Kostić T, Momčilović S, Perišić ZD, et al. Manifestations of Lyme carditis. International Journal of Cardiology. 2017;232:24-32. doi:10.1016/j.ijcard.2016.12.169.

538. Nagi KS, Joshi R, Thakur RK. Cardiac manifestations of Lyme disease: a review. Canadian Journal of Cardiology. 1996;12(5):503-6.

539. Esfandiar N, Beebe-Peat T, Quinlan A, et al. Lyme carditis complicated by polymorphic ventricular tachycardia and cardiac arrest: a case report. Journal of Investigative Medicine High Impact Case Reports. 2022;10:23247096221098333. doi:10.1177/23247096221098333.

540. Stein C, Migliavaca CB, Colpani V, et al. Amiodarone for arrhythmia in patients with chagas disease: a systematic review and individual patient data meta-analysis. PLOS Neglected Tropical Diseases. 2018;12(8):e0006742. doi:10.1371/journal.pntd.0006742.

541. Soto-Becerra R, Bazan V, Bautista W, et al. Ventricular tachycardia in the setting of chagasic cardiomyopathy: use of voltage mapping to characterize endoepicardial nonischemic scar distribution. Circulation: Arrhythmia and Electrophysiology. 2017;10(11):e004950. doi:10.1161/CIRCEP.116.004950.

542. Rassi FM, Minohara L, Rassi A, et al. Systematic review and meta-analysis of clinical outcome after implantable cardioverter-defibrillator therapy in patients with chagas heart disease. JACC: Clinical Electrophysiology. 2019;5(10):1213-23. doi:10.1016/j.jacep.2019.07.003.

543. Eckart RE, Hruczkowski TW, Tedrow UB, et al. Sustained ventricular tachycardia associated with corrective valve surgery. Circulation. 2007;116(18):2005-11. doi:10.1161/CIRCULATIONAHA.107.703157.

544. Rodríguez-Mañero M., Barrio-López MT, Assi EA, et al. Primary prevention of sudden death in patients with valvular cardiomyopathy. Revista Española de Cardiología (Engl Ed). 2016;69(3):272-8. doi:10.1016/j.rec.2015.05.016.

545. Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular arrhythmias originating from the moderator band: Electrocardiographic characteristics and treatment by catheter ablation. Heart Rhythm. 2015;12(1):67-75. doi:10.1016/j.hrthm.2014.08.029.

546. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr Scand. 1971;60(5):559-64. doi:10.1111/j.1651-2227.1971.tb06990.x.

547. Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen’s syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994;35(3):326-30. doi:10.1002/ana.410350313.

548. Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A. 2005;102(23):8089-96; discussion 8086-8. doi:10.1073/pnas.0502506102.

549. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54(1):59-68. doi:10.1016/0002-8703(57)90079-0.

550. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993; 88(2):782-4. doi:10.1161/01.cir.88.2.782.

551. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011;124(20):2181-4. doi:10.1161/CIRCULATIONAHA.111.062182.

552. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010;55(8):783-8. doi:10.1016/j.jacc.2009.11.042.

553. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103(1):89-95. doi:10.1161/01.cir.103.1.89.

554. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292(11):1341-4. doi:10.1001/jama.292.11.1341.

555. Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67(13):1639-50. doi:10.1016/j.jacc.2015.12.063.

556. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62(4):760-81. doi:10.1124/pr.110.003723.

557. Ahn J, Kim HJ, Choi JI, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis. PLoS One. 2017;12(10):e0185680. doi:10.1371/journal.pone.0185680.

558. Went TR, Sultan W, Sapkota A, et al. A Systematic Review on the Role of Βeta-Blockers in Reducing Cardiac Arrhythmias in Long QT Syndrome Subtypes 1-3. Cureus. 2021;13(9):e17632. doi:10.7759/cureus.17632.

559. Yoshinaga M, Kucho Y, Sarantuya J, et al. Genetic characteristics of children and adolescents with long-QT syndrome diagnosed by school-based electrocardiographic screening programs. Circ Arrhythm Electrophysiol. 2014;7(1):107-12. doi:10.1161/CIRCEP.113.000426.

560. Rodríguez-Mañero M, Casado-Arroyo R, Sarkozy A, et al. The clinical significance of pregnancy in Brugada syndrome. Revista Española de Cardiología (Engl Ed). 2014;67(3):176-80. doi:10.1016/j.rec.2013.06.023.

561. Gupta T, Khera S, Kolte D, et al. Antiarrhythmic properties of ranolazine: A review of the current evidence. Int J Cardiol. 2015;187:66-74. doi:10.1016/j.ijcard.2015.03.324.

562. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34(12):1600-6. doi:10.1111/j.1540-8159.2011.03208.x.

563. Zareba W, Daubert JP, Beck CA, et al.; RAID Trial Investigators. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. J Am Coll Cardiol. 2018;72(6):636-45.

564. Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007;116(10):1137-44. doi:10.1161/CIRCULATIONAHA.107.707877.

565. Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19(12):1289-93. doi:10.1111/j.1540-8167.2008.01246.x.

566. Chorin E, Hu D, Antzelevitch C, et al. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Circ Arrhythm Electrophysiol. 2016;9(10):e004370. doi:10.1161/CIRCEP.116.004370.

567. Chorin E, Taub R, Medina A, et al. Long-term flecainide therapy in type 3 long QT syndrome. Europace. 2018;20(2):370-6. doi:10.1093/europace/euw439.

568. Windle JR, Geletka RC, Moss AJ, et al. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A: DeltaKPQ mutation. Ann Noninvasive Electrocardiol. 2001 6(2):153-8. doi:10.1111/j.1542-474x.2001.tb00100.x.

569. Umeda M, Morimoto A, Yokoyama K, et al. Despite medication, overdrive pacing is required to stabilize the electrical storm associated with acute coronary syndrome: a case report. J Cardiol. 2007;50(4):263-9.

570. Yoshida T, Naito Y, Nishimura K. Temporary ventricular overdrive pacing for electrical storm after coronary artery bypass grafting. Gen Thorac Cardiovasc Surg. 2011;59(11):756-9. doi:10.1007/s11748-010-0771-z.

571. Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation. 2010;122(13):1272-82. doi:10.1161/CIRCULATIONAHA.110.950147.

572. Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll Cardiol. 2012;59(1):91-2. doi:10.1016/j.jacc.2011.09.043.

573. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92(12):3381-6. doi:10.1161/01.cir.92.12.3381.

574. Hofferberth SC, Cecchin F, Loberman D, Fynn-Thompson F. Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. 2014;147(1):404-9. doi:10.1016/j.jtcvs.2013.07.064.

575. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol. 2011;57(7):802-12. doi:10.1016/j.jacc.2010.09.048.

576. Suzuki H, Horie M, Ozawa J, et al. Novel electrocardiographic criteria for short QT syndrome in children and adolescents. Europace. 2021;23(12):2029-38. doi:10.1093/europace/euab097.

577. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58(6):587-95. doi:10.1016/j.jacc.2011.03.038.

578. Dewi IP, Dharmadjati BB. Short QT syndrome: The current evidences of diagnosis and management. J Arrhythm. 2020;36(6):962-6. doi:10.1002/joa3.12439.

579. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63(13):1300-8. doi:10.1016/j.jacc.2013.09.078.

580. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation. 2003;108(8):965-70. doi:10.1161/01.CIR.0000085071.28695.C4.

581. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. JACC. 2004;43(8):1494-9. doi:10.1016/j.jacc.2004.02.034.

582. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105(11):1342-7. doi:10.1161/hc1102.105288.

583. Maury P, Hocini M, Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiology. 2005;5(1):25-34.

584. Marquez MF, Bonny A, Hemandez-Castillo E, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm. 2012;9(12):1995-2000. doi:10.1016/j.hrthm.2012.08.027.

585. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 2003;108(25):3092-6. doi:10.1161/01.CIR.0000104568.13957.4F.

586. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011;123(12):1270-9. doi:10.1161/CIRCULATIONAHA.110.972612.

587. Argenziano M, Antzelevitch C. Recent advances in the treatment of Brugada syndrome. Expert Review of Cardiovascular Therapy. 2018;16(6):387-404. doi:10.1080/14779072.2018.1475230.

588. Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with Long-QT and Brugada syndromes. Circulation. 2003;108(8):925-8. doi:10.1161/01.CIR.0000088781.99943.95.

589. Nademanee K, Haissaguerre M, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with early repolarization syndrome. Circulation. 2019;140(18):1477-90. doi:10.1161/CIRCULATIONAHA.118.039022.

590. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic Polymorphic Ventricular Tachycardia in Children A 7-Year Follow-up of 21 Patients. Circulation. 1995;91(5):1512-9. doi:10.1161/01.cir.91.5.1512.

591. Макаров Л. М., Курылева Т. А., Чупрова С. Н. Укорочение интервала PR, брадикардия и полиморфная желудочковая тахикардия. Клинико-электрокардиографический синдром с высоким риском внезапной смерти у детей. Кардиология. 2003;7:34-7.

592. Makarov L, Kyrileva T, Komoliatova T, et al. New ECG pattern in young patients with polymorphic catecholaminergic ventricular tachycardia. JACC. 2007;49(9):916-42.

593. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69-74. doi:10.1161/01.cir.0000020013.73106.d8.

594. Hayashi M, Denjoy I, Extramiana F, et al Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricutar tachycardia. Circulation. 2009;119(18):2426-34. doi:10.1161/CIRCULATIONAHA.108.829267.

595. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15(4):380-3. doi:10.1038/nm.1942.

596. Beaufort-Krol GC, Dijkstra SS, Bink-Boelkens MT. Natural history of ventricular premature contractions in children with a structurally normal heart: does origin matter? Europace. 2008;10(8):998-1003. doi:10.1093/europace/eun121.

597. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008;117(3):363-70. doi:10.1161/CIRCULATIONAHA.107.726372.

598. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008;51(17):1685-91. doi:10.1016/j.jacc.2008.01.033.

599. Koyak Z, de Groot JR, Van Gelder IC, et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol. 2012;5(1):101-10. doi:10.1161/CIRCEP.111.966754.

600. Gallego P, Gonzalez AE, Sanchez-Recalde A, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol. 2012;110(1):109-17. doi:10.1016/j.amjcard.2012.02.057.

601. Ghai A, Silversides C, Harris L, et al. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coll Cardiol. 2002;40(9):1675-80. doi:10.1016/s0735-1097(02)02344-6.

602. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356(9234):975-81. doi:10.1016/S0140-6736(00)02714-8.

603. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation. 2004;109(16):1994-2000. doi:10.1161/01.CIR.0000126495.11040.BD.

604. Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1(4):250-7. doi:10.1161/CIRCEP.108.776120.

605. Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126(16):1944-54. doi:10.1161/CIRCULATIONAHA.112.104786.

606. Atallah J, Gonzalez Corcia MC, Walsh EP; Participating Members of the Pediatric and Congenital Electrophysiology Society. Ventricular Arrhythmia and Life-Threatening Events in Patients With Repaired Tetralogy of Fallot. Am J Cardiol. 2020;132:126-32. doi:10.1016/j.amjcard.2020.07.012.

607. Koyak Z, de Groot JR, Bouma BJ, et al. Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int J Cardiol. 2013;167(4):1532-5. doi:10.1016/j.ijcard.2012.04.103.

608. Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol. 2015;8(1):110-6. doi:10.1161/CIRCEP.114.001975.

609. Miyazaki A, Sakaguchi H, Ohuchi H, et al. Efficacy of hemodynamic-based management of tachyarrhythmia after repair of tetralogy of Fallot. Circ J. 2012;76(12):2855-62. doi:10.1253/circj.cj-12-0208.

610. Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997;30(5):1368-73. doi:10.1016/s0735-1097(97)00316-1.

611. van Zyl M, Kapa S, Padmanabhan D, et al. Mechanism and outcomes of catheter ablation for ventricular tachycardia in adults with repaired congenital heart disease. Heart Rhythm. 2016;13(7):1449-54. doi:10.1016/j.hrthm.2016.03.002.

612. Laredo M, Frank R, Waintraub X, et al. Ten-year outcomes of monomorphic ventricular tachycardia catheter ablation in repaired tetralogy of Fallot. Arch Cardiovasc Dis. 2017;110(5):292-302. doi:10.1016/j.acvd.2017.01.009.

613. Kapel GF, Reichlin T, Wijnmaalen AP, et al. Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol. 2015;8(1):102-9. doi:10.1161/CIRCEP.114.001929.

614. Kapel GF, Sacher F, Dekkers OM, et al. Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping are the substrate for ventricular tachycardia in repaired Tetralogy of Fallot. Eur Heart J. 2017;38(4):268-76. doi:10.1093/eurheartj/ehw202.

615. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation. 2007;116(20):2241-52. doi:10.1161/CIRCULATIONAHA.

616. Collins KK, Schaffer MS, Liberman L, et al. Pediatric and Congenital Electrophysiology Society. Fascicular and nonfascicular left ventricular tachycardias in the young: an international multicenter study. J Cardiovasc Electrophysiol. 2013;24(6):640-8. doi:10.1111/jce.12105.

617. Schneider HE, Kriebel T, Jung K, et al. Catheter ablation of idiopathic left and right ventricular tachycardias in the pediatric population using noncontact mapping. Heart Rhythm. 2010;7(6):731-9. doi:10.1016/j.hrthm.2010.02.031.

618. Kammeraad JA, van Deurzen CH, Sreeram N, et al. Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol. 2004;44(5):1095-102. doi:10.1016/j.jacc.2004.05.073.

619. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49(10):1092-8. doi:10.1016/j.jacc.2006.09.054.

620. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation. 1998;97(5):451-6. doi:10.1161/01.cir.97.5.451.

621. Ishibashi K, Aiba T, Kamiya C, et al. Arrhythmia risk and β-blocker therapy in pregnant women with long QT syndrome. Heart. 2017;103(17):1374-9. doi:10.1136/heartjnl-2016-310617.

622. Cheung CC, Lieve KV, Roston TM, et al. Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. JACC Clin Electrophysiol. 2019;5(3):387-94. doi:10.1016/j. jacep.2018.10.019.

623. Wu L, Liang E, Fan S, et al. Effect of Pregnancy in Arrhythmogenic Right Ventricular Cardiomyopathy. Am J Cardiol. 2020;125(4):613-7. doi:10.1016/j.amjcard.2019.11.008.

624. Bauce B, Daliento L, Frigo G, et al. Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet Gynecol Reprod Biol. 2006;127(2):186-9. doi:10.1016/j.ejogrb.2005.10.011.

625. Gandjbakhch E, Varlet E, Duthoit G, et al. Pregnancy and newborn outcomes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Int J Cardiol. 2018;258:172-8. doi:10.1016/j.ijcard.2017.11.067.

626. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. doi:10.1093/eurheartj/ehy340.

627. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал. 2018;(3):91-134. doi:10.15829/1560-4071-2018-3-91-134.

628. Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol. 2006;126(2):268-9. doi:10.1016/j.ejogrb.2005.11.021.

629. Cleary-Goldman J, Salva CR, Infeld JI, Robinson JN. Verapamil-sensitive idiopathic left ventricular tachycardia in pregnancy. J Matern Fetal Neonatal Med. 2003;14(2):132-5.

630. Abello M, Peinado R, Merino JL, et al. Cardioverter defibrillator implantation in a pregnant woman guided with transesophageal echocardiography. Pacing Clin Electrophysiol. 2003;26(9):1913-4. doi:10.1046/j.1460-9592.2003.00293.x.

631. Tuzcu V, Kilinc OU. Implantable cardioverter defibrillator implantation without using fluoroscopy in a pregnant patient. Pacing Clin Electrophysiol. 2012;35(9):e265-6. doi:10.1111/j.1540-8159.2011.03221.x.

632. Driver K, Chisholm CA, Darby AE, et al. Catheter ablation of arrhythmia during pregnancy. Journal of Cardiovascular Electrophysiology. 2015;26(6):698-702. doi:10.1111/jce.1267.

633. Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. The American Journal of Cardiology. 2006;97(8):1206-12. doi:10.1016/j.amjcard.2005.11.041.

634. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG. 2002;109(12):1406-7. doi:10.1046/j.1471-0528.2002.02113.x.

635. Miyoshi T, Kamiya CA, Katsuragi S, et al. Safety and efficacy of implantable cardioverter-defibrillator during pregnancy and after delivery. Circulaton. 2013;77(5):1166-70. doi:10.1253/circj.cj-12-1275.

636. Hartz J, Clark BC, Ito S, et al. Transvenous nonfluoroscopic pace maker implantation during pregnancy guided by 3-dimensional electroanatomic mapping. HeartRhythm Case Reports. 2017;3(10):490-2. doi:10.1016/j.hrcr.2017.07.020.

637. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. European Journal of Heart Failure. 2017;19(9):1131-41. doi:10.1002/ejhf.780.

638. Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in pregnancy: a scientific statement from the American heart association. Circulation. 2015;132(18):1747-73. doi:10.1161/CIR.0000000000000300.

639. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the task force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal. 2011;32(24):3147-97. doi:10.1093/eurheartj/ehr218.

640. Benito B, Berruezo A. Brugada syndrome and pregnancy: delving into the role of sex hormones in ion channelopathies. Revista Española de Cardiología (Engl Ed). 2014;67(3):165-7. doi:10.1016/j.rec.2013.09.021.

641. Wang Z, Chen YW, Jiang YH, et al. Electrophysiological characteristics and therapeutic efficacy of radiofrequency ablation of focal atrial tachycardia originating from the right atrial appendage during pregnancy. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(10):859-65. doi:10.3760/cma.j.cn112148-20191104-00683.

642. Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. The New England Journal of Medicine. 2016;374(3):233-41. doi:10.1056/NEJMoa1505517.

643. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure. 2019;21(7):827-43. doi:10.1002/ejhf.1493.

644. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465-73. doi:10.1161/CIRCULATIONAHA.109.901496.

645. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal. 2017;38(35):2671-9. doi:10.1093/eurheartj/ehx355

646. Fröhlich GM, Holzmeister J, Hübler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99(16):1158-65. doi:10.1136/heartjnl-2013-304185.

647. Joglar JA, Wan EY, Chung MK, et al. Management of Arrhythmias After Heart Transplant: Current State and Considerations for Future Research. Circ Arrhythm Electrophysiol. 2021;14(3):e007954. doi:10.1161/CIRCEP.120.007954.

648. Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. Europace. 2021;23(1):73-81. doi:10.1093/europace/euaa268.

649. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-56. doi:10.1016/j.healun.2010.05.034.

650. Alba AC, Foroutan F, Ng Fat Hing NKV, et al. Incidence and predictors of sudden cardiac death after heart transplantation: A systematic review and meta-analysis. Clin Transplant. 2018;32(3):e13206. doi:10.1111/ctr.13206.

651. Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014;11(10):1684-90. doi:10.1016/j.hrthm.2014.07.016.

652. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96. doi:10.1093/eurheartj/ ehaa605. Erratum in: Eur Heart J. 2021;42(5):548-9. doi:10.1093/eurheartj/ehaa835.

653. Corrado D, Zorzi A. Sudden death in athletes. Int J Cardiol. 2017;237:67-70. doi:10.1016/j.ijcard.2017.03.034.

654. Holst AG, Winkel BG, Theilade J, et al. Incidence and etiology of sports-related sudden cardiac death in Denmark — implications for preparticipation screening. Heart Rhythm. 2010;7(10):1365-71. doi:10.1016/j.hrthm.2010.05.021.

655. Corrado D, Schmied C, Basso C, et al. Risk of sports: do we need a pre-participation screening for competitive and leisure athletes? Eur Heart J. 2011;32(8):934-44. doi:10.1093/eurheartj/ehq482.

656. Drezner JA, Peterson DF, Siebert DM, et al. Survival After Exercise-Related Sudden Cardiac Arrest in Young Athletes: Can We Do Better? Sports Health. 2019;11(1):91-8. doi:10.1177/1941738118799084.

657. Drezner JA, Rogers KJ, Horneff JG. Automated external defibrillator use at NCAA Division II and III universities. Br J Sports Med. 2011;45(15):1174-8. doi:10.1136/bjsm.2009.070052.

658. Malhotra A, Dhutia H, Finocchiaro G, et al. Outcomes of Cardiac Screening in Adolescent Soccer Players. N Engl J Med. 2018;379(6):524-34. doi:10.1056/NEJMoa1714719.

659. Maestrini V, Torlasco C, Hughes R, Moon JC. Cardiovascular Magnetic Resonance and Sport Cardiology: a Growing Role in Clinical Dilemmas. J Cardiovasc Transl Res. 2020;13(3):296-305.

660. Cohen MI, Triedman JK, Cannon BC, et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhyth. 2012;9(6):1006-24. doi:10.1016/j.hrthm.2012.03.050.

661. Elming MB, Nielsen JC, Haarbo J, et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation. 2017;136(19):1772-80. doi:10.1161/CIRCULATIONAHA.117.028829.

662. Wang S, Zhu W, Hamilton RM, et al. Diagnosis-specific characteristics of ventricular tachycardia in children with structurally normal hearts. Heart Rhythm. 2010;7(12):1725-31. doi:10.1016/j.hrthm.2010.07.037.

663. Ventricular arrhythmias. Clinical guidelines for pediatric cardiology and rheumatology. Edited by Shkolnikova M. A., Alekseeva E. I. M., 2011. Ch. 5. ss. 133-59. (In Russ.) Желудочковые аритмии. Клинические рекомендации по детской кардиологии и ревматологии. Под ред. Школьниковой М. А., Алексеевой Е. И. М., 2011. Гл. 5. сс. 133-59.

664. Gill JS, Ward DE, Camm AJ. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15(11 Pt 2): 2122-6. doi:10.1111/j.1540-8159.1992.tb03033.x.

665. Li G, Zhang L. The role of mexiletine in the management of long QT syndrome. J Electrocardiol. 2018;51(6):1061-5. doi:10.1016/j.jelectrocard.2018.08.035.

666. Yeh SJ, Kou HC, Lin FC, et al. Effects of oral diltiazem in paroxysmal supraventricular tachycardia. Am J Cardiol. 1983;52(3):271-8. doi:10.1016/0002-9149(83)90121-2.

667. Buckley MM, Grant SM, Goa KL, et al. Diltiazem. A reappraisal of its pharmacological properties and therapeutic use. Drugs. 1990;39(5):757-806. doi:10.2165/00003495-199039050-00009.

668. Lapage MJ, Bradley DJ, Dick M. 2nd. Verapamil in infants: an exaggerated fear? Pediatr Cardiol. 2013;34(7):1532-4. doi:10.1007/s00246-013-0739-8.

669. Kirk CR, Gibbs JL, Thomas R, et al. Cardiovascular collapse after verapamil in supraventricular tachycardia. Arch Dis Child. 1987;62(12):1265-6. doi:10.1136/adc.62.12.1265.

670. Blaufox AD, Felix GL, Saul JP. Pediatric Catheter Ablation Registry. Radiofrequency catheter ablation in infants </=18 months old: when is it done and how do they fare?: short-term data from the pediatric ablation registry. Circulation. 2001;104(23):2803-8. doi:10.1161/hc4801.100028.

671. Surman TL, Stuklis RG, Chan JC. Thoracoscopic Sympathectomy for Long QT Syndrome. Literature Review and Case Study. Heart Lung Circ. 2019;28(3):486-94. doi:10.1016/j.hlc.2018.02.005.

672. Wenger NK, Froelicher ES, Smith LK, et al. Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. Clin Pract Guidel Quick Ref Guide Clin. 1995;(17):1-23.

673. Thomas RJ, King M, Lui K, et al.; AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists, Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2007;50(14):1400-33. doi:10.1016/j.jacc.2007.04.033.

674. Morady F, Kadish AH, DiCarlo L, et al. Long term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation. 1990;82(6):2093-9. doi:10.1161/01.cir.82.6.2093.

675. Tada H, Hiratsuji T, Naito S, et al. Prevalence and characteristics of idiopathic outflow tract tachycardia with QRS alteration following catheter ablation requiring additional radiofrequency ablation at a different point in the outflow tract. Pacing Clinical Electrophysiology. 2004;27(9):1240-9. doi:10.1111/j.1540-8159.2004.00615.x.

676. Klein LS, Shih HT, Hackett FK, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation. 1992;85(5):1666-74. doi:10.1161/01.cir.85.5.1666.

677. Della Bella P, Baratto F, Tsiachris D, et al. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation. Circulation. 2013;127(13):1359-68. doi:10.1161/CIRCULATIONAHA.112.000872.

678. Koruth JS, Aryana A, Dukkipati SR, et al. Unusual complications of percutaneous epicardial access and epicardial mapping and ablation of cardiac arrhythmias. Circulation: Arrhythmia and Electrophysiology. 2011;4(6):882-8. doi:10.1161/CIRCEP.111.965731.

679. Roberts-Thomson KC, Steven D, Seller J, et al. Coronary artery injury due to catheter ablation in adults: presentations and outcomes. Circulation. 2009;120(15):1465-73. doi:10.1161/CIRCULATIONAHA.109.870790.

680. Makimoto H, Zhang Q, Tilz RR, et al. Aborted sudden cardiac death due to radiofrequency ablation within the coronary sinus and subsequent total occlusion of the circumflex artery. Journal of Cardiovascular Electrophysiology. 2013;24(8):929-32. doi:10.1111/jce.12083.

681. Schwartz PJ, Stramba–Badiate M, Crotti L, et al. Prevalence of the congenital long QT syndrome. Circulation. 2009;120(18):1761-7. doi:10.1161/CIRCULATIONAHA.109.863209.

682. Corrado D, Petticcia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. European Heart Journal. 2005;26(5):516-24. doi:10.1093/eurheartj/ehi108.

683. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascutar abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115(12):1643-55. doi:10.1161/CIRCULATIONAHA.107.181423.

684. Ljungqvist A, Jenoure P, Engebretsen L, et al. The International Olympic Committee (IOC) consensus statement on periodic health evaluation of elite athletes, March 2009. British Journal of Sports Medicine. 2009;43(9) 631-43. doi:10.1136/bjsm.2009.064394.

685. Steinvil A, Chundadze T, Zeltser D, et al. Mandatory etectrocardiographic screening of athletes to reduce their risk for sudden death: proven fact or wishful thinking? JACC. 2011;57(11):1291-6. doi:10.1016/j.jacc.2010.10.037.

686. Kaltman JR, Thompson PD, Lantos J, et al. Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. Circulation. 2011;123(17):1911-8. doi:10.1161/CIRCULATIONAHA.110.017228.

687. Narain R, Mayers J, Dhutia H, et al. Preventing sudden cardiac death in the young: results from a population-based screening program in the UK. European Journal of Preventive Cardiology. 2014;21:S1-S6. doi:10.1016/j.ihj.2014.10.194.

688. Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715-26. doi:10.1093/eurheartj/ehq271.

689. Ormondroyd E, Oates S, Parker M, et al. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications. Eur J Hum Genet. 2014;22(1):88-93. doi:10.1038/ejhg.2013.81.

690. Ingles J, Yeates L, Hunt L, et al. Health status of cardiac genetic disease patients and their at-risk relatives. Int J Cardiol. 2013;165(3):448-53. doi:10.1016/j.ijcard.2011.08.083.

691. Battista RN, Blancquaert I, Laberge AM, et al. Genetics in health care: an overview of current and emerging models. Public Health Genomics. 2012;15(1):34-45. doi:10.1159/000328846.

692. Nolan JP, Soar J, Zideman DA, et al.; ERC Guidelines Writing Group. European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation. 2010;81(10):1219-76. doi:10.1016/j.resuscitation.2010.08.021.

693. Monsieurs KG, Nolan JP, Bossaert LL, et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 1. Executive summary. Resuscitation. 2015;95:1-80. doi:10.1016/j.resuscitation.2015.07.038.

694. Chiu DT, Shapiro NI, Sun BC, et al. Are echocardiography, telemetry, ambulatory electrocardiography monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful tests? A preliminary investigation. J Emerg Med. 2014;47(1):113-8. doi:10.1016/j.jemermed.2014.01.018.

695. Школьникова М. А., Харлап М. С., Ильдарова Р. А. Генетически детерминированные нарушения ритма сердца. Российский кардиологический журнал. 2011;(1):8-25.

696. Adler A, Halkin A, Viskin S. Wearable cardioverter-defibrillators. Circulation. 2013;127(7): 854-60. doi:10.1161/CIRCULATIONAHA.112.146530.

697. Hallstrom AP, Ornato JP, Weisfeldt M, et al.; Public Access Defibrillation Trial Investigators. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med. 2004;351(7):637-46. doi:10.1056/NEJMoa040566.

698. Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med. 1996;125(9):763-9. doi:10.7326/0003-4819-125-9-199611010-00010.

699. Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail 2010;16(2):106-13. doi:10.1016/j.cardfail.2009.09.003.

700. Ottenberg AL, Mueller PS, Topazian RJ, et al. "It’s not broke, so let’s not try to fix it": why patients decline a cardiovascular implantable electronic device. Pacing Clin Electrophysiol 2014; 37(10):1306-14. doi:10.1111/pace.12433.

701. Sherazi S, Zareba W, Daubert JP, et al. Physicians’ knowledge and attitudes regarding implantable cardioverter-defibrillators. Cardiol J. 2010;17(3):267-73.

702. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44(5):681-92. doi:10.1016/s0277-9536(96)00221-3.

703. Lewis KB, Stacey D, Matlock DD. Making decisions about implantable cardioverter-defibrillators from implantation to end of life: an integrative review of patients’ perspectives. Patient. 2014;7(3):243-60. doi:10.1007/s40271-014-0055-2.

704. Bratton S, Taylor MK, Cortez P, et al. Does atenolol use during pregnancy cause small for gestational age neonates? A meta-analysis. J Perinat Med. 2024;52(8):858-62. doi:10.1515/jpm-2024-0114.

705. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.

706. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-55. doi:10.1056/NEJM199605233342101.

707. Schupp T, Behnes M, Abumayyaleh M, et al. Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias. J Cardiovasc Dev Dis. 2022;9(8):274.

708. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7.

709. Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. 2023;20(10):e175-e264.

710. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247(12):1707-14. doi:10.1001/jama.1982.03320370021023.

711. Hirsowitz G, Podrid PJ, Lampert S, et al. The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia. Am Heart J. 1986;111(5):852-60. doi:10.1016/0002-8703(86)90633-2.

712. Peltenburg PJ, Kallas D, Bos JM, et al. An international multicenter cohort study on β-blockers for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2022;145(5):333-44. doi:10.1161/CIRCULATIONAHA.121.056018.

713. Fogoros RN, Fiedler SB, Elson JJ. Efficacy of phenytoin in suppressing inducible ventricular tachyarrhythmias. Cardiovasc Drugs Ther. 1988;2(2):171-6. doi:10.1007/BF00051232.

714. Yager N, Wang K, Keshwani N, Torosoff M. Phenytoin as an effective treatment for polymorphic ventricular tachycardia due to QT prolongation in a patient with multiple drug intolerances. BMJ Case Rep. 2015; 2015: bcr2015209521. doi:10.1136/bcr-2015-209521.

715. Ito M, Maeda Y, Arita M, et al. Effects of oral 784 diltiazem on ventricular premature contractions. J Electrocardiol. 1986;19(1):59-66. doi:10.1016/s0022-0736(86)80008-5.

716. Yeh SJ, Wen MS, Wang CC, et al. Adenosine-sensitive ventricular tachycardia from the anterobasal left ventricle. J Am Coll Cardiol. 1997;30(5):1339-45. doi:10.1016/s0735-1097(97)00291-x.

717. Garson AJr, Gillette PC, McVey P, et al. Amiodarone treatment of critical arrhythmias in children and young adults. J Am Coll Cardiol. 1984;4(4):749-55. doi:10.1016/s0735-1097(84)80402-7.

718. Yu Y, Liting T, Xiaoqin W, et al. Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia. Orphanet J Rare Dis. 2023;18(1):380. doi:10.1186/s13023-023-02991-0.

719. Ильдарова РА., Щербакова НВ., Березницкая ВВ., Школьникова МА. Сердечные и внесердечные проявления синдрома Джервелла-Ланге-Нильсена. Вестник аритмологии. 2021;28(3):37-44. doi:10.35336/VA-2021-3-37-44.

720. Wang Y, Yang Y, Xu N, et al. Clinical characteristics and follow-up of complex arrhythmias associated with RYR2 gene mutations in children. Front Genet. 2024;15:1405437. doi:10.3389/fgene.2024.1405437.